<SEC-DOCUMENT>0000950103-25-015351.txt : 20251126
<SEC-HEADER>0000950103-25-015351.hdr.sgml : 20251126
<ACCEPTANCE-DATETIME>20251126161751
ACCESSION NUMBER:		0000950103-25-015351
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20251126
DATE AS OF CHANGE:		20251126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BARCLAYS BANK PLC
		CENTRAL INDEX KEY:			0000312070
		STANDARD INDUSTRIAL CLASSIFICATION:	COMMERCIAL BANKS, NEC [6029]
		ORGANIZATION NAME:           	02 Finance
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-287303
		FILM NUMBER:		251530494

	BUSINESS ADDRESS:	
		STREET 1:		1 CHURCHILL PLACE
		STREET 2:		CANARY WHARF
		CITY:			LONDON
		STATE:			X0
		ZIP:			E14 5HP
		BUSINESS PHONE:		0044-20-3555-4619

	MAIL ADDRESS:	
		STREET 1:		1 CHURCHILL PLACE
		STREET 2:		CANARY WHARF
		CITY:			LONDON
		STATE:			X0
		ZIP:			E14 5HP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BARCLAYS BANK PLC /ENG/
		DATE OF NAME CHANGE:	19990402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BARCLAYS BANK INTERNATIONAL LTD
		DATE OF NAME CHANGE:	19850313
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>dp237902_424b2-8075baml.htm
<DESCRIPTION>FORM 424B2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt"><B>Preliminary
Term Sheet</B></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt"><B>(To the Prospectus dated May 15,
2025, the Prospectus Supplement dated May 15, 2025 and Product Supplement EQUITY ARN-1 dated October 29, 2025)</B></FONT></P></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt; color: red"><B>Subject
    to Completion<BR>
    Dated November 26, 2025</B></FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt"><B>Filed
    Pursuant to Rule 424(b)(2)<BR>
    Registration Statement No. 333-287303</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #1F497D">
    <TD COLSPAN="2"><P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;Units</FONT></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">$10 principal amount
    per unit<BR>
    CUSIP No.&nbsp;</FONT></P></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: white"><FONT STYLE="font-size: 9pt">Pricing Date*</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: white"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">Settlement Date*</FONT></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">Maturity Date*</FONT></P></TD>
    <TD><P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 9pt">December&nbsp;&nbsp;&nbsp;&nbsp;,
    2025</FONT></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 9pt">December&nbsp;&nbsp;&nbsp;&nbsp;,
    2025</FONT></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 9pt">February&nbsp;&nbsp;&nbsp;&nbsp;,
    2027</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #1F497D">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: white"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 22.5pt; width: 109.5pt"></FONT></TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt; color: white">*Subject to change based on the actual date the
    notes are priced for initial sale to the public (the &ldquo;pricing date&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #046E87"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></P></TD>
    <TD STYLE="background-color: #C87D0E; font-size: 10pt"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: #5C255C; font-size: 10pt"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="background-color: #61961A; font-size: 10pt"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #1F497D">
    <TD COLSPAN="5">
    <P STYLE="color: white; font: bold 21pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Accelerated Return Notes<SUP>&reg;</SUP> Linked to
    the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF</P>
    <P STYLE="color: white; font: bold 21pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;Maturity
    of approximately 14 months</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;3-to-1
    upside exposure to increases in the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF (the
    &ldquo;Market Measure&rdquo;), subject to a capped return of [21.00% to 25.00%]</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;1-to-1
    downside exposure to decreases in the Market Measure, with 100% of your principal at risk</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;All
    payments occur at maturity and are subject to the credit risk of Barclays Bank PLC.</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;No
    periodic interest payments</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;In
    addition to the underwriting discount set forth below, the notes include a hedging-related charge of $0.05 per unit. See &ldquo;Structuring
    the Notes.&rdquo;</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;Limited
    secondary market liquidity, with no exchange listing</P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"></P>
    <P STYLE="color: white; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>&nbsp;The
notes are our unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC. The notes are not covered
by the U.K. Financial Services Compensation Scheme or insured by the U.S. Federal Deposit Insurance Corporation or any other governmental
agency or deposit insurance agency of the United States, the United Kingdom, or any other jurisdiction.</P></TD></TR>
  <TR>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The notes are being issued by Barclays Bank PLC (&ldquo;Barclays&rdquo;).
There are important differences between the notes and a conventional debt security, including different investment risks and certain additional
costs. See &ldquo;Risk Factors&rdquo; and &ldquo;Additional Risk Factors&rdquo; beginning on page TS-7 of this term sheet and &ldquo;Risk
Factors&rdquo; beginning on page PS-7 of product supplement EQUITY ARN-1 and beginning on page S-9 of the prospectus supplement.</P>

<P STYLE="font: bold 5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Our initial estimated value of the notes, based on our internal pricing
models, is expected to be between $8.965 and $9.465 <FONT STYLE="background-color: white">per unit on the pricing date, which is less
than the public offering price listed below.</FONT></B> See &ldquo;Summary&rdquo; on the following page, &ldquo;Risk Factors&rdquo; beginning
on page TS-7 of this term sheet and &ldquo;Structuring the Notes&rdquo; below for additional information. The actual value of your notes
at any time will reflect many factors and cannot be predicted with accuracy.</P>

<P STYLE="font: bold 5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Notwithstanding and to the exclusion of any other term of the notes
or any other agreements, arrangements or understandings between Barclays and any holder or beneficial owner of the notes (or the trustee
on behalf of the holders of the notes), by acquiring the notes, each holder or beneficial owner of the notes acknowledges, accepts, agrees
to be bound by, and consents to the exercise of, any U.K. Bail-in Power by the relevant U.K. resolution authority. All payments are subject
to the risk of exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority. See &ldquo;Consent to U.K. Bail-in Power&rdquo;
on page TS-3 and &ldquo;Risk Factors&rdquo; beginning on page TS-7 of this term sheet.</P>

<P STYLE="font: bold 5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">None of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
any state securities commission, or any other regulatory body has approved or disapproved of these securities or determined if this Note
Prospectus (as defined below) is truthful or complete. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: bold 5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" ALIGN="CENTER" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center; font-size: 10pt"><U>Per Unit</U></TD>
    <TD STYLE="width: 32%; text-align: center; font-size: 10pt"><U>Total</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Public offering price<SUP>(1)&#9;</SUP></TD>
    <TD STYLE="font-size: 10pt; text-align: center">$&#9;10.000</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$&#9;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Underwriting discount<SUP>(1)&#9;</SUP></TD>
    <TD STYLE="font-size: 10pt; text-align: center">$&#9;0.175</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$&#9;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Proceeds, before expenses, to Barclays<SUP>&#9;</SUP></TD>
    <TD STYLE="font-size: 10pt; text-align: center">$&#9;9.825</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$&#9;</TD></TR>
  </TABLE>
<P STYLE="font: bold 5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt">(1)</TD><TD>For any purchase of 300,000 units or more in a single transaction by an individual investor or in combined transactions with the investor&rsquo;s
household in this offering, the public offering price and the underwriting discount will be $9.950 per unit and $0.125 per unit, respectively.
See &ldquo;Supplement to the Plan of Distribution&rdquo; below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>The notes:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" ALIGN="CENTER" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; font-size: 10pt; text-align: center"><B>Are Not FDIC Insured</B></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Are Not Bank Guaranteed</B></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>May Lose Value</B></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">BofA Securities</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">December &nbsp;&nbsp;&nbsp;, 2025</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 20pt Arial, Helvetica, Sans-Serif; color: #5B862B; margin: 0pt 0">Summary</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Accelerated Return Notes<SUP>&reg;</SUP> Linked to the State Street<SUP>&reg;</SUP>
SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027 (the &ldquo;notes&rdquo;)
are our unsecured and unsubordinated obligations and are not deposit liabilities of Barclays. The notes are not covered by the U.K. Financial
Services Compensation Scheme or insured by the U.S. Federal Deposit Insurance Corporation or any other governmental agency or deposit
insurance agency of the United States, the United Kingdom or any other jurisdiction. <B>The notes will rank equally with all of our other
unsecured and unsubordinated debt. Any payments due on the notes, including any repayment of principal, will be subject to the credit
risk of Barclays and to the risk of exercise of any U.K. Bail-in Power (as described herein) or any other resolution measure by any relevant
U.K. resolution authority.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The notes provide you a leveraged return, subject to a cap, if the Ending
Value of the Market Measure, which is the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech
ETF (the &ldquo;Market Measure&rdquo;), is greater than the Starting Value. If the Ending Value is less than the Starting Value, you will
lose all or a portion of the principal amount of your notes. Any payments on the notes will be calculated based on the $10 principal amount
per unit and will depend on the performance of the Market Measure, subject to our credit risk. See &ldquo;Terms of the Notes&rdquo; below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">On the cover page of this term sheet, we have provided the estimated
value range for the notes. This range of estimated values was determined based on our internal pricing models, which take into account
a number of variables, including volatility, interest rates and our internal funding rates, which are our internally published borrowing
rates and the economic terms of certain related hedging arrangements. This range of estimated values may not correlate on a linear basis
with the range of Capped Value for the notes. The estimated value of the notes calculated on the pricing date is expected to be less than
the public offering price and will be set forth in the final term sheet made available to investors in the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The economic terms of the notes (including the Capped Value) are based
on our internal funding rates, which may vary from the levels at which our benchmark debt securities trade in the secondary market, and
the economic terms of certain related hedging arrangements. The difference between these rates, as well as the underwriting discount,
the hedging-related charge and other amounts described below, will reduce the economic terms of the notes. For more information about
the estimated value and the structuring of the notes, see &ldquo;Structuring the Notes&rdquo; below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 20pt; color: #5B862B"><FONT STYLE="font-size: 18pt">Terms of the Notes</FONT></TD>
    <TD STYLE="padding-left: 10pt; font-size: 20pt; color: #5B862B"><FONT STYLE="font-size: 18pt">Redemption Amount Determination</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Issuer:</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Barclays Bank PLC (&ldquo;Barclays&rdquo;)</FONT></TD>
    <TD STYLE="padding-left: 10pt; width: 55%"><FONT STYLE="font-size: 10pt">On the maturity date, you will receive a cash payment per unit determined as follows:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Principal Amount:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$10.00 per unit</FONT></TD>
    <TD ROWSPAN="11" STYLE="padding-left: 10pt; color: #5B8F22; font-weight: bold"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 155.25pt; width: 261.75pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Term:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Approximately 14 months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Market Measure:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF (Bloomberg symbol: &ldquo;XBI&rdquo;)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Starting Value:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Closing Market Price of the Market Measure on the pricing date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Ending Value:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The average of the Closing Market Price of the Market Measure <I>times</I> the Price Multiplier on each calculation day occurring during the Maturity Valuation Period. The scheduled calculation days are subject to postponement in the event of Market Disruption Events, as described beginning on page PS-27 of product supplement EQUITY ARN-1.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Price Multiplier:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">1, subject to adjustment for certain events relating to the Market Measure, as described beginning on page PS-30 of product supplement EQUITY ARN-1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Participation Rate:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">300%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Capped Value:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[$12.10 to $12.50] per unit, which represents a return of [21.00% to 25.00%] over the principal amount. The actual Capped Value will be determined on the pricing date.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Maturity Valuation Period:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Five scheduled calculation days shortly before the maturity date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Fees and Charges:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The public offering price of the notes includes the underwriting discount of $0.175 per unit listed on the cover page and a hedging-related charge of $0.05 per unit described in &ldquo;Structuring the Notes&rdquo; below.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F2F2F2; color: #5B8F22; font-weight: bold"><FONT STYLE="font-size: 10pt">Calculation Agents:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Barclays and BofA Securities, Inc. (&ldquo;BofAS&rdquo;)</FONT></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The terms and risks of the notes are contained in this term sheet and
in the following:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;</FONT></TD><TD>Product supplement EQUITY ARN-1 dated October 29, 2025:<BR>
<A HREF="http://www.sec.gov/Archives/edgar/data/312070/000095010325013808/dp236328_424b2-equityarn1.htm">http://www.sec.gov/Archives/edgar/data/312070/000095010325013808/dp236328_424b2-equityarn1.htm</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;</FONT></TD><TD>Series A MTN prospectus supplement dated May 15, 2025:<BR>
<A HREF="http://www.sec.gov/Archives/edgar/data/312070/000095010325006051/dp228678_424b2-prosupp.htm">http://www.sec.gov/Archives/edgar/data/312070/000095010325006051/dp228678_424b2-prosupp.htm</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;</FONT></TD><TD>Prospectus dated May 15, 2025:<BR>
<A HREF="http://www.sec.gov/Archives/edgar/data/312070/000119312525120720/d925982d424b2.htm">http://www.sec.gov/Archives/edgar/data/312070/000119312525120720/d925982d424b2.htm</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">These documents (together, the &ldquo;Note Prospectus&rdquo;) have been
filed as part of a registration statement with the SEC, which may, without cost, be accessed on the SEC website as indicated above or
obtained from us, Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated (&ldquo;MLPF&amp;S&rdquo;) or BofAS by calling 1-800-294-1322.
Before you invest, you should read the Note Prospectus, including this term sheet, and the other documents that we have filed with the
SEC for information about us and this offering. Any prior or contemporaneous oral statements and any other written materials you may have
received are superseded by the Note Prospectus. Capitalized terms used but not defined in this term sheet have the meanings set forth
in product supplement EQUITY ARN-1. Unless otherwise indicated or unless the context requires otherwise, all references in this term sheet
to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or similar references are to Barclays.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&ldquo;Accelerated Return Notes<SUP>&reg;</SUP>&rdquo; and &ldquo;ARNs<SUP>&reg;</SUP>&rdquo;
are the registered service marks of Bank of America Corporation, the parent company of MLPF&amp;S and BofAS.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Consent to U.K. Bail-in Power</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Notwithstanding and to the exclusion of any other term of the notes
or any other agreements, arrangements or understandings between us and any holder or beneficial owner of the notes (or the trustee on
behalf of the holders of the notes), by acquiring the notes, each holder or beneficial owner of the notes acknowledges, accepts, agrees
to be bound by, and consents to the exercise of, any U.K. Bail-in Power by the relevant U.K. resolution authority.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Under the U.K. Banking Act 2009, as amended, the relevant U.K. resolution
authority may exercise a U.K. Bail-in Power in circumstances in which the relevant U.K. resolution authority is satisfied that the resolution
conditions are met. These conditions include that a U.K. bank or investment firm is failing or is likely to fail to satisfy the Financial
Services and Markets Act 2000 (the &ldquo;FSMA&rdquo;) threshold conditions for authorization to carry on certain regulated activities
(within the meaning of section 55B FSMA) or, in the case of a U.K. banking group company that is a European Economic Area (&ldquo;EEA&rdquo;)
or third country institution or investment firm, that the relevant EEA or third country relevant authority is satisfied that the resolution
conditions are met in respect of that entity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The U.K. Bail-in Power includes any write-down, conversion, transfer,
modification and/or suspension power, which allows for (i) the reduction or cancellation of all, or a portion, of the principal amount
of, or interest on, or any other amounts payable on, the notes; (ii) the conversion of all, or a portion, of the principal amount of,
or interest on, or any other amounts payable on, the notes into shares or other securities or other obligations of Barclays or another
person (and the issue to, or conferral on, the holder or beneficial owner of the notes of such shares, securities or obligations); (iii)
the cancellation of the notes and/or (iv) the amendment or alteration of the maturity of the notes, or the amendment of the amount of
interest or any other amounts due on the notes, or the dates on which interest or any other amounts become payable, including by suspending
payment for a temporary period; which U.K. Bail-in Power may be exercised by means of a variation of the terms of the notes solely to
give effect to the exercise by the relevant U.K. resolution authority of such U.K. Bail-in Power. Each holder and beneficial owner of
the notes further acknowledges and agrees that the rights of the holders or beneficial owners of the notes are subject to, and will be
varied, if necessary, solely to give effect to, the exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority. For
the avoidance of doubt, this consent and acknowledgment is not a waiver of any rights holders or beneficial owners of the notes may have
at law if and to the extent that any U.K. Bail-in Power is exercised by the relevant U.K. resolution authority in breach of laws applicable
in England.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">For more information, please see &ldquo;Risk Factors&mdash;Issuer-related
Risks&mdash;You May Lose Some or All of Your Investment If Any U.K. Bail-in Power Is Exercised by the Relevant U.K. Resolution Authority&rdquo;
in this term sheet as well as &ldquo;U.K. Bail-in Power,&rdquo; &ldquo;Risk Factors&mdash;Risks Relating to the Securities Generally&mdash;Regulatory
action in the event a bank or investment firm in the Group is failing or likely to fail, including the exercise by the relevant U.K. resolution
authority of a variety of statutory resolution powers, could materially adversely affect the value of any securities&rdquo; and &ldquo;Risk
Factors&mdash;Risks Relating to the Securities Generally&mdash;Under the terms of the securities, you have agreed to be bound by the exercise
of any U.K. Bail-in Power by the relevant U.K. resolution authority&rdquo; in the accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Investor Considerations</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><B>You may wish to consider an investment in the notes if:</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%"><B>The notes may not be an appropriate investment for you if:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    anticipate that the Market Measure will increase moderately from the Starting Value to the Ending Value.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are willing to risk a loss of principal and return if the Market Measure decreases from the Starting Value to the Ending Value.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    accept that the return on the notes will be capped.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are willing to forgo the interest payments that are paid on conventional interest-bearing debt securities.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are willing to forgo dividends and other benefits of directly owning shares of the Market Measure or the securities held by the Market
    Measure.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are willing to accept a limited or no market for sales prior to maturity, and understand that the market prices for the notes, if any,
    will be affected by various factors, including our actual and perceived creditworthiness, the inclusion in the public offering price of
    the underwriting discount, the hedging-related charge and other amounts, as described above.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are willing and able to assume our credit risk, as issuer of the notes, for all payments under the notes, including the Redemption Amount.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
are willing and able to consent to the exercise of any U.K. Bail-in Power by U.K. resolution authorities.</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    believe that the Market Measure will decrease from the Starting Value to the Ending Value or that it will not increase sufficiently over
    the term of the notes to provide you with your desired return.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    seek principal repayment or preservation of capital.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    seek an uncapped return on your investment.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    seek interest payments or other current income on your investment.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    want to receive dividends or have other benefits of directly owning shares of the Market Measure or the securities held by the Market
    Measure.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    seek an investment for which there will be a liquid secondary market.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are unwilling or unable to take market risk on the notes or to take our credit risk as issuer of the notes.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings; color: #5B8F22">&sect;&#9;</FONT>&nbsp;You
    are unwilling or unable to consent to the exercise of any U.K. Bail-in Power by U.K. resolution authorities.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We urge you to consult your investment, legal, tax, accounting and other
advisors before you invest in the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Hypothetical Payout Profile and Examples of Payments
at Maturity</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The graph below is based on <B>hypothetical</B> numbers and values.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 53%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Accelerated Return Notes<SUP>&reg;</SUP></B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 175.5pt; width: 183pt"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; width: 47%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: #F2F2F2">This graph reflects the returns on the notes,
    based on the Participation Rate of 300% and a hypothetical Capped Value of $12.30 per unit (the midpoint of the Capped Value range of
    [$12.10 to $12.50]). The green line reflects the returns on the notes, while the dotted gray line reflects the returns of a direct investment
    in the Market Measure, excluding dividends.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: #F2F2F2">&nbsp;</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: #F2F2F2">This graph has been prepared for purposes
    of illustration only.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: #F2F2F2">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The following table and examples are for purposes of illustration only.
They are based on <B>hypothetical </B>values and show <B>hypothetical</B> returns on the notes. They illustrate the calculation of the
Redemption Amount and total rate of return based on a hypothetical Starting Value of 100.00, the Participation Rate of 300%, a hypothetical
Capped Value of $12.30 per unit and a range of hypothetical Ending Values. <B>The actual amount you receive and the resulting total rate
of return will depend on the actual Starting Value, Ending Value and Capped Value, and whether you hold the notes to maturity.</B> The
following examples do not take into account any tax consequences from investing in the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">For recent actual prices of the Market Measure, see &ldquo;The Market
Measure&rdquo; section below. The Ending Value will not include any income generated by dividends paid on the Market Measure, which you
would otherwise be entitled to receive if you invested in the Market Measure directly. In addition, all payments on the notes are subject
to issuer credit risk.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 90%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 25%; border-bottom: Black 1pt solid; text-align: center"><B>Ending Value</B></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1pt solid; text-align: center"><B>Percentage Change from the Starting Value to the Ending Value</B></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1pt solid; text-align: center"><B>Redemption Amount per Unit</B></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 23%; border-bottom: Black 1pt solid; text-align: center"><B>Total Rate of Return on the Notes</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">0.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-100.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-100.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">50.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-50.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$5.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-50.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">70.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-30.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$7.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-30.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">80.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-20.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$8.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-20.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">90.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-10.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$9.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-10.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">95.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-5.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$9.50</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-5.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">97.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-3.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$9.70</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">-3.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;&nbsp; 100.00<SUP>(1)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">0.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$10.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">0.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">102.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$10.60</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">103.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$10.90</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">105.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$11.50</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">107.67</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.67%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;&nbsp; $12.30<SUP>(2)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">110.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$12.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">120.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$12.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">130.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$12.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">150.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">50.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$12.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23.00%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">200.00</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">100.00%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$12.30</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23.00%</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD>The <B>hypothetical </B>Starting Value of 100.00 used in these examples has been chosen for illustrative purposes only, and does not
represent a likely actual Starting Value for the Market Measure.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 18pt">(2)</TD><TD>The Redemption Amount per unit cannot exceed the <B>hypothetical </B>Capped Value.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><B>Redemption Amount Calculation Examples:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 33%"><B>Example 1</B></TD>
    <TD STYLE="width: 67%">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2">The Ending Value is 50.00, or 50.00% of the Starting Value:</TD></TR>
  <TR>
    <TD COLSPAN="2">Starting Value: 100.00</TD></TR>
  <TR>
    <TD COLSPAN="2">Ending Value: 50.00</TD></TR>
  <TR>
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 21pt; width: 52.5pt"></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD><B>= $5.00</B> Redemption Amount per unit</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 33%"><B>Example 2</B></TD>
    <TD STYLE="width: 67%">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2">The Ending Value is 102.00, or 102.00% of the Starting Value:</TD></TR>
  <TR>
    <TD>Starting Value: 100.00</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Ending Value: 102.00</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><IMG SRC="image_005.jpg" ALT="" STYLE="height: 20.25pt; width: 156pt"></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD><B>= $10.60</B> Redemption Amount per unit</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 33%"><B>Example 3</B></TD>
    <TD STYLE="width: 67%">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2">The Ending Value is 130.00, or 130.00% of the Starting Value:</TD></TR>
  <TR>
    <TD>Starting Value: 100.00</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>Ending Value: 130.00</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 20.25pt; width: 156pt"></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD><B>= $19.00, however, because the Redemption Amount for the notes cannot exceed the hypothetical Capped Value, the Redemption Amount will be $12.30 per unit</B></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Risk Factors</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><I>There are important differences between the notes and a conventional
debt security. An investment in the notes involves significant risks, including those listed below. You should carefully review the more
detailed explanation of risks relating to the notes in the &ldquo;Risk Factors&rdquo; sections beginning on page PS-7 of product supplement
EQUITY ARN-1 and page S-9 of the Series A MTN prospectus supplement identified above. We also urge you to consult your investment, legal,
tax, accounting, and other advisors before you invest in the notes.</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Structure-related Risks</U></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>Depending on the performance of the Market Measure as measured shortly before the maturity date, your investment may result in a loss;
there is no guaranteed return of principal.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>Your return on the notes may be less than the yield you could earn by owning a conventional fixed or floating rate debt security of
comparable maturity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>Your investment return is limited to the return represented by the Capped Value and may be less than a comparable investment directly
in shares of the Market Measure or the securities held by the Market Measure.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Issuer-related Risks</U></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>Payments on the notes are subject to our credit risk, and any actual or perceived changes in our creditworthiness are expected to
affect the value of the notes. If we become insolvent or are unable to pay our obligations, you may lose your entire investment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>You may lose some or all of your investment if any U.K. Bail-in Power is exercised by the relevant U.K. resolution authority. Notwithstanding
and to the exclusion of any other term of the notes or any other agreements, arrangements or understandings between Barclays and any holder
or beneficial owner of the notes (or the trustee on behalf of the holders of the notes), by acquiring the notes, each holder or beneficial
owner of the notes acknowledges, accepts, agrees to be bound by, and consents to the exercise of, any U.K. Bail-in Power by the relevant
U.K. resolution authority as set forth under &ldquo;Consent to U.K. Bail-in Power&rdquo; in this term sheet. Accordingly, any U.K. Bail-in
Power may be exercised in such a manner as to result in you and other holders and beneficial owners of the notes losing all or a part
of the value of your investment in the notes or receiving a different security from the notes, which may be worth significantly less than
the notes and which may have significantly fewer protections than those typically afforded to debt securities. Moreover, the relevant
U.K. resolution authority may exercise the U.K. Bail-in Power without providing any advance notice to, or requiring the consent of, the
holders and beneficial owners of the notes. The exercise of any U.K. Bail-in Power by the relevant U.K. resolution authority with respect
to the notes will not be a default or an Event of Default (as each term is defined in the senior debt securities indenture) and the trustee
will not be liable for any action that the trustee takes, or abstains from taking, in either case, in accordance with the exercise of
the U.K. Bail-in Power by the relevant U.K. resolution authority with respect to the notes. See &ldquo;Consent to U.K. Bail-in Power&rdquo;
in this term sheet as well as &ldquo;U.K. Bail-in Power,&rdquo; &ldquo;Risk Factors&mdash;Risks Relating to the Securities Generally&mdash;Regulatory
action in the event a bank or investment firm in the Group is failing or likely to fail, including the exercise by the relevant U.K. resolution
authority of a variety of statutory resolution powers, could materially adversely affect the value of any securities&rdquo; and &ldquo;Risk
Factors&mdash;Risks Relating to the Securities Generally&mdash;Under the terms of the securities, you have agreed to be bound by the exercise
of any U.K. Bail-in Power by the relevant U.K. resolution authority&rdquo; in the accompanying prospectus supplement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Valuation- and Market-related Risks</U></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The estimated value of your notes is based on our internal pricing models. Our internal pricing models take into account a number
of variables and are based on a number of subjective assumptions, which may or may not materialize, typically including volatility, interest
rates, and our internal funding rates. These variables and assumptions are not evaluated or verified on an independent basis and may prove
to be inaccurate. Different pricing models and assumptions of different financial institutions could provide valuations for the notes
that are different from our estimated value.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The estimated value is based on a number of variables, including volatility, interest rates and our internal funding rates. Our internal
funding rates may vary from the levels at which our benchmark debt securities trade in the secondary market. As a result of this difference,
the estimated value referenced in this term sheet may be lower if such estimated value was based on the levels at which our benchmark
debt securities trade in the secondary market.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The estimated value of your notes is expected to be lower than the public offering price of your notes. This difference is expected
as a result of certain factors, such as the inclusion in the public offering price of the underwriting discount, the hedging-related charge,
the estimated profit, if any, that we or any of our affiliates expect to earn in connection with structuring the notes, and the estimated
cost which we may incur in hedging our obligations under the notes, as further described in &ldquo;Structuring the Notes&rdquo; below.
If you attempt to sell the notes prior to maturity, their market value may be lower than the price you paid for the notes and lower than
the estimated value because the secondary market prices take into consideration the levels at which our debt securities trade in the secondary
market, but do not take into account such fees, charges and other amounts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The estimated value of the notes will not be a prediction of the prices at which MLPF&amp;S, BofAS or its affiliates, or any of our
affiliates or any other third parties may be willing to purchase the notes from you in secondary market transactions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 53.85pt; text-indent: 0.15pt">The price at which you may be able
to sell your notes in the secondary market at any time will be influenced by many factors that cannot be predicted, such as market conditions,
and any bid and ask spread for similar size trades, and may be substantially less than our estimated value of the notes. Any sale prior
to the maturity date could result in a substantial loss to you.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 53.85pt; text-indent: 0.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>A trading market is not expected to develop for the notes. None of us, MLPF&amp;S, BofAS or our respective affiliates is obligated
to make a market for, or to repurchase, the notes. There is no assurance that any party will be willing to purchase your notes at any
price in any secondary market.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Conflict-related Risks</U></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>Our business, hedging and trading activities, and those of MLPF&amp;S, BofAS and our respective affiliates (including trades in shares
of the Market Measure or the securities held by the Market Measure), and any hedging and trading activities we, MLPF&amp;S, BofAS or our
respective affiliates engage in for our clients&rsquo; accounts, may affect the market value and return of the notes and may create conflicts
of interest with you.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>There may be potential conflicts of interest involving the calculation agents, which are Barclays and BofAS. We have the right to
appoint and remove the calculation agents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Market Measure-related Risks</U></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The sponsor and advisor of the Market Measure may adjust the Market Measure in a way that could adversely affect the value of the
notes and the amount payable on the notes, and these entities have no obligation to consider your interests.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>You will have no rights of a holder of shares of the Market Measure or the securities held by the Market Measure, and you will not
be entitled to receive securities or dividends or other distributions by the issuers of those securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>While we, MLPF&amp;S, BofAS or our respective affiliates may from time to time own shares of the Market Measure or the securities
held by the Market Measure, we, MLPF&amp;S, BofAS and our respective affiliates do not control the Market Measure or the issuers of those
securities, and have not verified any disclosure made by any other company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.6pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>There are liquidity and management risks associated with the Market Measure.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.6pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The performance of the Market Measure may not correlate with the performance of the securities held by the Market Measure as well
as the net asset value per share of the Market Measure, especially during periods of market volatility when the liquidity and the market
price of shares of the Market Measure and/or the securities held by the Market Measure may be adversely affected, sometimes materially.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.6pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The payments on the notes will not be adjusted for all corporate events that could affect the Market Measure. See &ldquo;Description
of the ARNs&mdash;Anti-Dilution and Discontinuance Adjustments Relating to Underlying Funds&rdquo; in product supplement EQUITY ARN-1.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><B><U>Tax-related Risks</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.6pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Wingdings; color: #5B862B">&sect;</FONT></TD><TD>The U.S. federal income tax consequences of an investment in the notes are uncertain. There is no direct legal authority regarding
the proper U.S. federal income tax treatment of the notes, and we do not plan to request a ruling from the Internal Revenue Service (the
&ldquo;IRS&rdquo;). Consequently, significant aspects of the tax treatment of the notes are uncertain, and the IRS or a court might not
agree with the treatment of the notes as prepaid forward contracts, as described below under &ldquo;Tax Consequences.&rdquo; If the IRS
were successful in asserting an alternative treatment for the notes, the tax consequences of the ownership and disposition of the notes
could be materially and adversely affected.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">Even if the treatment of the notes is
respected, the IRS may assert that the notes constitute &ldquo;constructive ownership transactions&rdquo; within the meaning of Section
1260 of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), in which case gain recognized in respect of the notes
that would otherwise be long-term capital gain and that was in excess of the &ldquo;net underlying long-term capital gain&rdquo; (as defined
in Section 1260) would be treated as ordinary income, and a notional interest charge would apply as if that income had accrued for tax
purposes at a constant yield over the notes&rsquo; term. Our special tax counsel has not expressed an opinion with respect to whether
the constructive ownership rules apply to the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 35.85pt; text-indent: 0in">In addition, in 2007 the Treasury Department
and the IRS released a notice requesting comments on various issues regarding the U.S. federal income tax treatment of &ldquo;prepaid
forward contracts&rdquo; and similar instruments. Any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect. You
should review carefully the sections of the accompanying prospectus supplement entitled &ldquo;Material U.S. Federal Income Tax Consequences&mdash;Tax
Consequences to U.S. Holders&mdash;Notes Treated as Prepaid Forward Contracts&rdquo; and, if you are a non-U.S. holder, &ldquo;&mdash;Tax
Consequences to Non-U.S. Holders,&rdquo; and consult your tax advisor regarding the U.S. federal tax consequences of an investment in
the notes (including the potential application of the constructive ownership rules, possible alternative treatments and the issues presented
by the 2007 notice), as well as tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 35.85pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: #5B862B">Additional Risk Factors</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: #5B862B">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>The securities held by the Market Measure are concentrated in one
industry.</B> As a result, the securities that will determine the performance of the notes are concentrated in one industry. Although
an investment in the notes will not give holders any ownership or other direct interests in the securities held by the Market Measure,
the return on the notes will be subject to certain risks similar to those</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">associated with direct equity investments in the biotechnology industry.
Accordingly, by investing in the notes, you will not benefit from the diversification which could result from an investment linked to
companies that operate in multiple industries.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Adverse conditions in the biotechnology industry may reduce your
return on the notes.</B> All of the stocks held by the Market Measure are issued by companies whose primary lines of business are directly
associated with the biotechnology industry. The profitability of these companies is largely dependent on, among other things, demand for
the companies&rsquo; products, regulatory influences on the biotechnology market (including healthcare reform and receipt of regulatory
approvals and compliance with complex regulatory requirements), pricing and reimbursement from third party payors, continued innovation
and successful development of new products, talent attraction and retention, maintaining intellectual property rights and industry competition.
Any adverse developments affecting the biotechnology industry could adversely affect the price of the Market Measure and the value of
the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Market Measure</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">All information contained in this term sheet regarding the Market Measure
has been derived from publicly available information, without independent verification. This information reflects the policies of, and
is subject to change by, the SPDR<SUP>&reg;</SUP> Series Trust and SSGA Funds Management, Inc. (&ldquo;<B>SSGA FM</B>&rdquo;). The Market
Measure is an investment portfolio maintained and managed by SSGA FM, the investment adviser to the Market Measure. The consequences of
any discontinuance of the Market Measure are discussed in the section entitled &ldquo;Description of the ARNs&mdash;Anti-Dilution and
Discontinuance Adjustments Relating to Underlying Funds&rdquo; in product supplement EQUITY ARN-1. None of us, the calculation agents,
MLPF&amp;S or BofAS accepts any responsibility for the calculation, maintenance or publication of the Market Measure or any successor.
Neither we nor any agent has independently verified the accuracy or completeness of any information with respect to the Market Measure
in connection with the offer and sale of the notes. The Market Measure is an exchange-traded fund that trades on the NYSE Arca, Inc. under
the ticker symbol &ldquo;XBI.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Market Measure seeks to provide investment results that, before
fees and expenses, correspond generally to the total return performance of the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index.
The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index is a modified equal-weighted index that is designed to measure the performance
of the Global Industry Classification Standard (&ldquo;<B>GICS<SUP>&reg;</SUP></B>&rdquo;) biotechnology sub-industry of the S&amp;P Total
Market Index. The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index may also include companies in the life sciences tools and
services supplementary sub-industry. For more information about the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index, please
see &ldquo;The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index&rdquo; below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">In seeking to track the performance of the S&amp;P<SUP>&reg;</SUP> Biotechnology
Select Industry Index, the Market Measure employs a &ldquo;sampling&rdquo; strategy, which means that the Market Measure is not required
to purchase all of the securities represented in the S&amp;P<SUP>&reg; </SUP>Biotechnology Select Industry Index. Instead, the Market
Measure may purchase a subset of the securities in the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index in an effort to hold
a portfolio of securities with generally the same risk and return characteristics as the S&amp;P Biotechnology Select Industry Index.
The quantity of holdings in the Market Measure will be based on a number of factors, including asset size of the Market Measure. Based
on its analysis of these factors, SSGA FM either may invest the Market Measure&rsquo;s assets in a subset of securities in the S&amp;P<SUP>&reg;
</SUP>Biotechnology Select Industry Index or may invest the Market Measure&rsquo;s assets in substantially all of the securities represented
in the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index in approximately the same proportions as the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index, as determined by SSGA FM to be in the best interest of the Market Measure in pursuing its objective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">While SSGA FM seeks to track the performance of the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index (i.e., achieve a high degree of correlation with the S&amp;P<SUP>&reg;</SUP> Biotechnology Select
Industry Index), the Market Measure&rsquo;s return may not match the return of the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry
Index for a number of reasons. For example, the return on the sample of securities purchased by the Market Measure (or the return on securities
not included in the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index) may not correlate precisely with the return of the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index. The Market Measure incurs a number of operating expenses not applicable to the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index, and incurs costs in buying and selling securities. In addition, the Market Measure may not be fully
invested at times, either as a result of cash flows into or out of the Market Measure or reserves of cash held by the Market Measure to
meet redemptions. SSGA FM may attempt to track the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index&rsquo;s return by investing
in fewer than all of the securities in the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index, or in some securities not included
in the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index, potentially increasing the risk of divergence between the Market Measure&rsquo;s
return and that of the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index. Changes in the composition of the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index and regulatory requirements also may impact the Market Measure&rsquo;s ability to match the return
of the S&amp;P Biotechnology Select Industry Index. SSGA FM may apply one or more &ldquo;screens&rdquo; or investment techniques to refine
or limit the number or types of issuers included in the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index in which the Market
Measure may invest. Application of such screens or techniques may result in investment performance below that of the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index and may not produce results expected by SSGA FM. Index tracking risk may be heightened during times
of increased market volatility or other unusual market conditions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The SPDR<SUP>&reg;</SUP> Series Trust is a registered investment company
that consists of a separate investment portfolio for the Market Measure. Information provided to or filed with the SEC by the SPDR<SUP>&reg;</SUP>
Series Trust pursuant to the Securities Act of 1933, as amended, and the Investment Company Act of 1940, as amended, can be located by
reference to SEC file numbers 333-57793 and 811-08839, respectively, through the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B><I>The S&amp;P</I></B><I><SUP>&reg;</SUP> <B>Biotechnology Select
Industry Index</B></I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">All information contained in this term sheet regarding the S&amp;P<SUP>&reg;</SUP>
Biotechnology Select Industry Index including, without limitation, its make-up, method of calculation and changes in its components, has
been derived from publicly available information, without independent verification. This information reflects the policies of, and is
subject to change by, S&amp;P Dow Jones Indices LLC (&ldquo;<B>S&amp;P Dow Jones</B>&rdquo;). The S&amp;P<SUP>&reg;</SUP> Biotechnology
Select Industry Index is calculated, maintained and published by S&amp;P Dow Jones. S&amp;P Dow Jones has no obligation to continue to
publish, and may discontinue publication of, the S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index is one
of the S&amp;P Select Industry Indices (collectively, the &ldquo;<B>Select Industry Indices</B>&rdquo; and each, a &ldquo;<B>Select Industry
Index</B>&rdquo;). The Select Industry Indices are modified equal-weighted indices that are designed to measure the performance of stocks
composing specific GICS<SUP>&reg;</SUP> sub-industries or groups of sub-industries in the S&amp;P Total Market Index (the &ldquo;<B>S&amp;P
TMI</B>&rdquo;). Membership is based on a company&rsquo;s GICS<SUP>&reg;</SUP> classification, as well as liquidity and market capitalization
requirements. The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index is designed to measure the performance of the GICS<SUP>&reg;</SUP>
biotechnology sub-industry of the S&amp;P TMI. The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry Index may also include companies
in the life sciences tools &amp; services supplementary</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">sub-industry. The S&amp;P<SUP>&reg;</SUP> Biotechnology Select Industry
Index is reported by Bloomberg L.P. under the ticker symbol &ldquo;SPSIBI.&rdquo; For additional information about the S&amp;P TMI, please
see &ldquo;The S&amp;P Total Market Index&rdquo; below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B><I>The S&amp;P Total Market Index</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The S&amp;P TMI offers broad market exposure to companies of all market
capitalizations, including all eligible U.S. common equities with a primary listing on the New York Stock Exchange, NYSE Arca, NYSE American,
Nasdaq Global Select Market, Nasdaq Select Market, Nasdaq Capital Market, Cboe BZX, Cboe BYX, Cboe EDGA or Cboe EDGX exchanges. Only U.S.
companies are eligible for inclusion in the S&amp;P TMI.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B><I>The S&amp;P<SUP>&reg;</SUP> Select Industry Indices</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Select Industry Index Eligibility</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">To qualify for membership in a Select Industry Index,
at each quarterly rebalancing, a company must satisfy the following criteria:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">be a
member of the S&amp;P TMI;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">be included
in the relevant GICS<SUP>&reg;</SUP> sub-industries for the relevant Select Industry Index (stocks included in such sub-industry, &ldquo;<B>primary
stocks</B>&rdquo;);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">meet
one of the following float-adjusted market capitalization (&ldquo;<B>FMC</B>&rdquo;) and float-adjusted liquidity ratio (&ldquo;<B>FALR</B>&rdquo;)
requirements:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">be a
current constituent, have an FMC greater than or equal to US$300 million and have an FALR greater than or equal to 50%;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">have
an FMC greater than or equal to US$500 million and an FALR greater than or equal to 90%; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">have
an FMC greater than or equal to US$400 million and an FALR greater than or equal to 150%.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">Notwithstanding the foregoing, to be eligible for
inclusion in the S&amp;P<SUP>&reg;</SUP> Banks Select Industry Index, a company&rsquo;s FMC must be above US$ 2 billion and its FALR must
be above 100%, and existing constituents of the S&amp;P<SUP>&reg;</SUP> Banks Select Industry Index are removed at the quarterly rebalancing
date if either their FMC falls below US$ 1 billion or their FALR falls below 50%.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">In the event that fewer than 35 stocks are selected
for each Select Industry Index using the eligible primary stocks, certain indices will select stocks for inclusion from a supplementary
list of highly correlated sub-industries (supplementary stocks) based on a process established by S&amp;P Dow Jones. Additionally, minimum
FMC requirements may be relaxed for all Select Industry Indices to ensure that there are at least 22 stocks in each Select Industry Index
as of each rebalancing effective date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Liquidity. </I>An FALR, defined as the annual dollar
value traded divided by the FMC, is used to measure liquidity. Using composite pricing and all publicly reported U.S. consolidated volume,
annual dollar value traded is defined as the average closing price multiplied by the historical volume over the 365 calendar days prior
to the evaluation date. This is reduced to the available trading period for stocks that do not have 365 calendar days of trading history.
In these cases, the dollar value traded available as of the evaluation date is annualized. Liquidity requirements are reviewed during
the quarterly rebalancings. The price, shares outstanding and IWF (as defined below) as of the evaluation date are used to calculate the
FMC. The evaluation date is the last business day of the month prior to the rebalancing effective date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Takeover Restrictions. </I>At the discretion of
S&amp;P Dow Jones, constituents with shareholder ownership restrictions defined in company bylaws may be deemed ineligible for inclusion
in a Select Industry Index. Ownership restrictions preventing entities from replicating the index weight of a stock may be excluded from
the eligible universe or removed from the relevant Select Industry Index. S&amp;P Dow Jones will provide up to five days advance notification
of a deletion between rebalancings due to ownership restrictions. If S&amp;P Dow Jones&rsquo;s index committee (the &ldquo;<B>Index Committee</B>&rdquo;)
decides to remove or exclude a company, that company is ineligible for re-entry or inclusion, respectively, for at least one full calendar
year, beginning with the subsequent rebalance.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Multiple Share Classes. </I>Some companies in the
S&amp;P TMI are represented by multiple share classes. As of December 2015, each company in the Select Industry Indices is represented
once by the primary listing, which is generally the most liquid share line.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Calculation of the Select Industry Indices</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">The Select Industry Indices are equal-weighted, with
adjustments to individual constituent weights to ensure concentration and liquidity requirements, and calculated by means of the divisor
methodology used by S&amp;P Dow Jones for the Select Industry Indices.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">The index value of each Select Industry Index is simply
the market value of that Select Industry Index divided by the index divisor:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in">Index Value = (Index Market Value) / Divisor</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in">Index Market Value =<IMG SRC="image_007.jpg" ALT="" STYLE="height: 11.25pt; width: 132pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">where <I>N</I> is the number of stocks in the index,
P<SUB>i</SUB> is the price of stock <I>i</I>, Shares<SUB>i</SUB> is total shares outstanding of stock <I>i</I>, IWF<SUB>i</SUB> is the
float factor of stock <I>i</I> (as defined below), and AWF<SUB>i</SUB> is the adjustment factor of stock <I>i</I> assigned at each index
rebalancing date, <I>t</I>, which makes all index constituents modified market capitalization equal (and, therefore, equal weight), while
maintaining the total market value of the overall index. The AWF for each index constituent, <I>i</I>, at rebalancing date, <I>t</I>,
is calculated by:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in">AWF<SUB>i,t</SUB> = Z / (N &times; FloatAdjustedMarketValue<SUB>i,t</SUB>)</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">where Z is an index-specific constant set for the purpose of deriving
the AWF and, therefore, each stock&rsquo;s share count used in the index calculation (often referred to as modified index shares).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Float Adjustment.</I> Float adjustment means that
the number of shares outstanding is reduced to exclude shares that are held by other publicly traded companies, government agencies or
certain types of strategic shareholders from the calculation of the index value because such shares are not available to investors. The
goal of float adjustment is to adjust each company&rsquo;s total shares outstanding for long-term strategic shareholders, who often have
interests such as maintaining control rather than securing the shorter-term economic fortunes of the company. Generally, these long-term
strategic shareholders include, but are not limited to, officers and directors, private equity, venture capital and special equity firms,
asset managers and insurance companies with direct board of director representation, other publicly traded companies that hold shares,
holders of restricted shares, company-sponsored employee share plans/trusts, defined contribution plans/savings, and investment plans,
foundations or family trusts associated with the company, government entities at all levels (other than government retirement/pension
funds), sovereign wealth funds and any individual person who controls a 5% or greater stake in a company as reported in regulatory filings.
Restricted shares are generally not included in total shares outstanding except for shares held as part of a lock-up agreement. Shares
that are not considered outstanding are also not included in the available float. These generally include treasury stock, stock options,
equity participation units, warrants, preferred stock, convertible stock and rights.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">For each component, S&amp;P Dow Jones calculates an
Investable Weight Factor (&ldquo;<B>IWF</B>&rdquo;), which represents the portion of the total shares outstanding that are considered
part of the public float for purposes of the relevant Select Industry Index.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Divisor. </I>Continuity in index values of each
Select Industry Index is maintained by adjusting its divisor for all changes in its constituents&rsquo; share capital after its base date.
This includes additions and deletions to the relevant Select Industry Index, rights issues, share buybacks and issuances and non-zero
price spin-offs. The value of each Select Industry Index&rsquo;s divisor over time is, in effect, a chronological summary of all changes
affecting the base capital of that Select Industry Index. The divisor of each Select Industry Index is adjusted such that the index value
of that Select Industry Index at an instant just prior to a change in base capital equals the index value of that Select Industry Index
at an instant immediately following that change.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Constituent Weightings</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">At each quarterly rebalancing, constituents are initially
equal weighted with adjustments to ensure that, for a given theoretical portfolio value (&ldquo;<B>TPV</B>&rdquo;), each constituent&rsquo;s
weight in the relevant Select Industry Index does not exceed 4.5% of the FMC or the value that can be traded in three days. No stock can
have a weight greater than 4.5% in the relevant Select Industry Index. TPVs are reviewed annually in September, incorporating index-linked
exchange traded product assets under management (&ldquo;<B>AUM</B>&rdquo;) using the below process:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Determine
the maximum aggregate AUM tracking the relevant Select Industry Index over the past year, based on index-linked exchange traded product&rsquo;s
AUM from the previous September, December, March and June, as well as the latest available month-end data point.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Round
the maximum value up to the nearest billion.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Add
a 20% buffer to the result and again round up to the nearest billion for the final TPV.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">If there are no index-linked exchange traded products
tracking the relevant Select Industry Index, the TPV for that index is set at US$ 2 billion. Any updates to the TPV for an index are made
at the discretion of the Index Committee and announced to clients with ample lead time.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">S&amp;P Dow Jones Indices calculates a maximum constituent
weight for each index constituent equal to the lesser of (i) 4.5%, (ii) 3 <I>times</I> the ratio of the three-month median daily value
traded (&ldquo;<B>MDVT</B>&rdquo;) of the index constituent to its TPV and (iii) 4.5% <I>times</I> the ratio of the index constituent&rsquo;s
FMC to its TPV.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">The reference date for assessing the 3-month MDVT
and stock price is after the close on the last business day of February, May, August and November for the rebalancings effective after
the close on the third Friday of March, June, September and December, respectively.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">Each constituent&rsquo;s initial equal weight is compared
to the calculated maximum constituent weight, and the constituent&rsquo;s weight is set to the lesser of the maximum constituent weight
or the initial equal weight. If the resulting index weights do not sum to 100%, any excess weights are iteratively redistributed to the
uncapped constituents.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">If all constituents are capped and the resulting index
weights still do not sum to 100%, the constraints are relaxed in the following order:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maximum
liquidity weight multiplier in increments of 0.1,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Single
stock cap in increments of 0.1%,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TPV
decreasing in increments of US$100 million.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">The process is repeated iteratively until a feasible
solution is found. The single stock weight constraint&rsquo;s upper limit for the iterative process is 4.8%.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Secondary Reweighting. </I>If, on the third to
last business day of March, June, September or December, the aggregate weight of companies with index weights greater than 4.8% exceeds
50%, index weights reset to the previously determined weights using the data from that quarter's reference date, with an effective date
as of after the close of the last business day of the month.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">If a secondary reweighting is triggered, and existing
constituent(s) were dropped since the prior quarterly rebalancing, the secondary reweighting re-runs the reweighting process using the
same data from the latest quarterly rebalancing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Maintenance of the Select Industry Indices</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Rebalancing. </I>The membership of the Select Industry
Indices is reviewed quarterly. Rebalancings occur after the closing on the third Friday of the quarter ending month. The reference date
for additions and deletions is after the closing of the last trading date of the previous month. Closing prices as of the Wednesday prior
to the second Friday of the last month of the quarter are used for setting index weights.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Additions. </I>Stocks are added between rebalancings
only if a deletion in the applicable Select Industry Index causes the stock count to fall below 22. In those cases, each stock deletion
is accompanied by a stock addition. The new stock will be added to the applicable Select Industry Index at the weight of the deleted company.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Deletions. </I>A stock is deleted from the applicable
Select Industry Index if the S&amp;P TMI drops the stock. If a stock deletion causes the number of stocks in the applicable Select Industry
Index to fall below 22, each stock deletion is accompanied by a corresponding stock addition. In the case of mergers involving two index
constituents, the merged entity remains in the applicable Select Industry Index provided it satisfies the eligibility criteria. If the
merged entity qualifies for index inclusion, the stock deemed the target is dropped, the index shares for the acquirer will remain unchanged,
and the weightings of the remaining constituents adjust proportionally.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>GICS<B><SUP>&reg;</SUP></B> Reclassifications.
</I>If a constituent&rsquo;s GICS<SUP>&reg;</SUP> classification changes to an ineligible sub-industry for a given Select Industry Index,
the constituent is removed from that Select Industry Index at the subsequent rebalancing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Spin-Offs</I>. The S&amp;P Select Industry Indices
follow the S&amp;P TMI treatment of spin-offs. In general, both the parent and spin-off company remain in the relevant Select Industry
Index until the subsequent rebalancing. The spin-off company is added to the relevant Select Industry Index at a zero price at the close
of the day before the ex-date. No price adjustment is applied to the parent and there is no divisor change. If the spin-off company is
dropped from S&amp;P TMI the weight of the spun-off company is added back to the parent stock&rsquo;s weight after at least one day of
trading.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in"><I>Adjustments. </I>The table below summarizes the
treatment of certain corporate actions.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 29%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Corporate
Action</B></P></TD>
    <TD STYLE="width: 71%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Treatment</B></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Change in shares outstanding</B></TD>
    <TD>Shares outstanding changes are offset by an adjustment factor (AWF). There is no change to the market capitalization of the relevant Select Industry Index and no divisor adjustment.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Split/reverse split</B></TD>
    <TD>Shares outstanding are adjusted by the split ratio. Stock price is adjusted by the split ratio. There is no change to the market capitalization of the relevant Select Industry Index and no divisor adjustment.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Change in IWF</B></TD>
    <TD>IWF changes are offset by an AWF. There is no change to the market capitalization of the relevant Select Industry Index and no divisor adjustment.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Ordinary dividend</B></TD>
    <TD>When a company pays an ordinary cash dividend, the relevant Select Industry Index does not make any adjustments to the price or shares of the stock. As a result, there are no divisor adjustments to that Select Industry Index.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Special dividend</B></TD>
    <TD>The stock price is adjusted by the amount of the dividend. The net change to the market capitalization of the relevant Select Industry Index causes a divisor adjustment.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Rights offering</B></TD>
    <TD>All rights offerings that are in the money on the ex-date are applied under the assumption that the rights are fully subscribed. The stock price is adjusted by the value of the rights and the shares outstanding are increased by the rights ratio. The change in price and shares is offset by an AWF to keep the market capitalization (stock weight) of the relevant Select Industry Index unchanged. There is no change to the market capitalization of that Select Industry Index and no divisor adjustment.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Governance of the Select Industry Indices</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">The Index Committee maintains the Select Industry
Indices. All Index Committee members are full-time professional members of S&amp;P Dow Jones&rsquo;s staff. The Index Committee meets
regularly. At each meeting, the Index Committee reviews pending corporate actions that may affect the Select Industry Indices constituents,
statistics comparing the composition of the Select Industry Indices to the market, companies that are being considered as candidates for
addition to a Select Industry Index and any significant market events. In addition, the Index Committee may revise index policy covering
rules for selecting companies, treatment of dividends, share counts or other matters.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B><I>The following graph shows the daily historical performance of
the Market Measure in the period from January 1, 2015 through November 20, 2025. We obtained this historical data from Bloomberg L.P.
We have not independently verified the accuracy or completeness of the information obtained from Bloomberg L.P. On November 20, 2025,
the Closing Market Price of the Market Measure was $113.83. The graph below may reflect adjustments in response to certain actions, such
as stock splits and reverse stock splits.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Historical Performance of the Market Measure</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_008.jpg" ALT="" STYLE="height: 275.25pt; width: 432.75pt"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B><I>This historical data on the Market Measure is not necessarily
indicative of the future performance of the Market Measure or what the value of the notes may be. Any historical upward or downward trend
in the price per share of the Market Measure during any period set forth above is not an indication that the price per share of the Market
Measure is more or less likely to increase or decrease at any time over the term of the notes.</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Before investing in the notes, you should consult
publicly available sources for the prices of the Market Measure.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Supplement to the Plan of Distribution</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Under our distribution agreement with BofAS, BofAS will purchase the
notes from us as principal at the public offering price indicated on the cover of this term sheet, less the indicated underwriting discount.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">BofAS has advised us that MLPF&amp;S will purchase the notes from BofAS
for resale, and will receive a selling concession in connection with the sale of the notes in an amount up to the full amount of underwriting
discount set forth on the cover of this term sheet.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We will pay a fee to LFT Securities, LLC for providing certain electronic
platform services with respect to this offering, which reduces the economic terms of the notes to you. An affiliate of BofAS has an ownership
interest in LFT Securities, LLC.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We may deliver the notes against payment therefor in New York, New York
on a date that is greater than one business day following the pricing date. Under Rule 15c6-1 of the Securities Exchange Act of 1934,
trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree
otherwise. Accordingly, if the initial settlement of the notes occurs more than one business day from the pricing date, purchasers who
wish to trade the notes more than one business day prior to the original issue date will be required to specify alternative settlement
arrangements to prevent a failed settlement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The notes will not be listed on any securities exchange. In the original
offering of the notes, the notes will be sold in minimum investment amounts of 100 units. If you place an order to purchase the notes,
you are consenting to MLPF&amp;S and/or one of its affiliates acting as a principal in effecting the transaction for your account.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">MLPF&amp;S and BofAS may repurchase and resell the notes, with repurchases
and resales being made at prices related to then-prevailing market prices or at negotiated prices, and these prices will include MLPF&amp;S&rsquo;s
and BofAS&rsquo;s trading commissions and mark-ups or mark-downs. MLPF&amp;S and BofAS may act as principal or agent in these market-making
transactions; however, neither is obligated to engage in any such transactions. BofAS has advised us that, at MLPF&amp;S&rsquo;s and BofAS&rsquo;s
discretion, for a short, undetermined initial period after the issuance of the notes, MLPF&amp;S and BofAS may offer to buy the notes
in the secondary market at a price that may exceed the initial estimated value of the notes. Any price offered by MLPF&amp;S or BofAS
for the notes will be based on then-prevailing market conditions and other considerations, including the performance of the Market Measure,
the remaining term of the notes and our creditworthiness. However, none of us, MLPF&amp;S, BofAS or any of our respective affiliates is
obligated to purchase your notes at any price or at any time, and we cannot assure you that we, MLPF&amp;S, BofAS or any of our respective
affiliates will purchase your notes at a price that equals or exceeds the initial estimated value of the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The value of the notes shown on your account statement produced by MLPF&amp;S&nbsp;&nbsp;will
be based on BofAS&rsquo;s estimate of the value of the notes if BofAS or another of its affiliates were to make a market in the notes,
which it is not obligated to do. That estimate will be based upon the price that BofAS may pay for the notes in light of then-prevailing
market conditions and other considerations, as mentioned above, and will include transaction costs. At certain times, this price may be
higher than or lower than the initial estimated value of the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The distribution of the Note Prospectus in connection with these offers
or sales will be solely for the purpose of providing investors with the description of the terms of the notes that was made available
to investors in connection with their initial offering. Secondary market investors should not, and will not be authorized to, rely on
the Note Prospectus for information regarding Barclays or for any purpose other than that described in the immediately preceding sentence.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">An investor&rsquo;s household, as referenced on the cover of this term
sheet, will generally include accounts held by any of the following, as determined by MLPF&amp;S in its discretion and acting in good
faith based upon information then available to MLPF&amp;S:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.15pt"></TD><TD STYLE="width: 15.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the investor&rsquo;s spouse (including a domestic partner), siblings, parents, grandparents, spouse&rsquo;s parents, children and
grandchildren, but excluding accounts held by aunts, uncles, cousins, nieces, nephews or any other family relationship not directly above
or below the individual investor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.15pt"></TD><TD STYLE="width: 15.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a family investment vehicle, including foundations, limited partnerships and personal holding companies, but only if the beneficial
owners of the vehicle consist solely of the investor or members of the investor&rsquo;s household as described above; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.15pt"></TD><TD STYLE="width: 15.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a trust where the grantors and/or beneficiaries of the trust consist solely of the investor or members of the investor&rsquo;s household
as described above; provided that, purchases of the notes by a trust generally cannot be aggregated together with any purchases made by
a trustee&rsquo;s personal account.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Purchases in retirement accounts will not be considered part of the
same household as an individual investor&rsquo;s personal or other non-retirement account, except for individual retirement accounts (&ldquo;IRAs&rdquo;),
simplified employee pension plans (&ldquo;SEPs&rdquo;), savings incentive match plan for employees (&ldquo;SIMPLEs&rdquo;) and single-participant
or owners only accounts (i.e., retirement accounts held by self-employed individuals, business owners or partners with no employees other
than their spouses).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Please contact your MLPF&amp;S financial advisor if you have any questions
about the application of these provisions to your specific circumstances or think you are eligible.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #5B862B; font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Structuring the Notes</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The notes are our debt securities, the return on which is linked to
the performance of the Market Measure. As is the case for all of our debt securities, including our market-linked notes, the economic
terms of the notes reflect our actual or perceived creditworthiness at the time of pricing. The economic terms of the notes are based
on our internal funding rates, which are our internally published borrowing rates based on variables such as market benchmarks, our appetite
for borrowing and our existing obligations coming to maturity. Our internal funding rates may vary from the levels at which our benchmark
debt securities trade in the secondary market. Our estimated value on the pricing date will be based on our internal funding rates. Our
estimated value of the notes may be lower if such valuation were based on the levels at which our benchmark debt securities trade in the
secondary market.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">At maturity, we are required to pay the Redemption Amount to holders
of the notes, which will be calculated based on the $10 per unit principal amount and will depend on the performance of the Market Measure.
In order to meet these payment obligations, at the time we issue the notes, we may choose to enter into certain hedging arrangements (which
may include call options, put options or other derivatives) with BofAS or one of its affiliates. The terms of these hedging arrangements
are determined by seeking bids from market participants, including MLPF&amp;S, BofAS and their or our affiliates, and take into account
a number of factors, including our creditworthiness, interest rate movements, the volatility of the Market Measure, the tenor of the notes
and the tenor of the hedging arrangements. The economic terms of the notes and their initial estimated value depend in part on the terms
of these hedging arrangements, any estimated profit that we or any of our affiliates expect to earn in connection with structuring the
notes and estimated costs which we may incur in hedging our obligations under the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">BofAS has advised us that the hedging arrangements will include a hedging-related
charge of approximately $0.05 per unit, reflecting an estimated profit to be credited to BofAS from these transactions. Since hedging
entails risk and may be influenced by unpredictable market forces, additional profits and losses from these hedging arrangements may be
realized by us, BofAS or any third party hedge providers.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">For further information, see &ldquo;Risk Factors&mdash;Valuation- and
Market-related Risks&rdquo; beginning on page PS-9 and &ldquo;Use of Proceeds and Hedging&rdquo; on page PS-23 of product supplement EQUITY
ARN-1.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 14pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #9BBB59 6pt solid; font-size: 10pt; color: #5B862B">Linked to the State Street<SUP>&reg;</SUP> SPDR<SUP>&reg;</SUP>&nbsp;S&amp;P<SUP>&reg;</SUP>&nbsp;Biotech ETF, due February&nbsp;&nbsp;&nbsp;&nbsp;, 2027</TD></TR></TABLE><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 20pt Arial, Helvetica, Sans-Serif; color: rgb(91,134,43); margin: 0pt 0">Tax Consequences</P>

<P STYLE="color: #5B862B; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">You should review carefully the sections in the accompanying prospectus
supplement entitled &ldquo;Material U.S. Federal Income Tax Consequences&mdash;Tax Consequences to U.S. Holders&mdash;Notes Treated as
Prepaid Forward Contracts&rdquo; and, if you are a non-U.S. holder, &ldquo;&mdash;Tax Consequences to Non-U.S. Holders.&rdquo; The following
discussion, when read in combination with those sections, constitutes the full opinion of our special tax counsel, Davis Polk &amp; Wardwell
LLP, regarding the material U.S. federal income tax consequences of owning and disposing of the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Based on current market conditions, in the opinion of our special tax
counsel, it is reasonable to treat the notes for U.S. federal income tax purposes as prepaid forward contracts with respect to the Market
Measure. Assuming this treatment is respected, upon a sale or exchange of the notes (including redemption at maturity), you should recognize
gain or loss equal to the difference between the amount realized on the sale or exchange and your tax basis in the notes, which should
equal the amount you paid to acquire the notes. Subject to the application of the constructive ownership rules, any gain or loss recognized
on your notes should be treated as long-term capital gain or loss if you hold your notes for more than a year, whether or not you are
an initial purchaser of notes at the issue price. The notes could be treated as constructive ownership transactions within the meaning
of Section 1260 of the Code, in which case any gain recognized in respect of the notes that would otherwise be long-term capital gain
and that was in excess of the &ldquo;net underlying long-term capital gain&rdquo; (as defined in Section 1260) would be treated as ordinary
income, and a notional interest charge would apply as if that income had accrued for tax purposes at a constant yield over the notes&rsquo;
term. Our special tax counsel has not expressed an opinion with respect to whether the constructive ownership rules apply to the notes.
Accordingly, U.S. holders should consult their tax advisors regarding the potential application of the constructive ownership rules.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The IRS or a court may not respect the treatment of the notes described
above, in which case the timing and character of any income or loss on the notes could be materially and adversely affected. In addition,
in 2007 the U.S. Treasury Department and the IRS released a notice requesting comments on the U.S. federal income tax treatment of &ldquo;prepaid
forward contracts&rdquo; and similar instruments. The notice focuses in particular on whether to require investors in these instruments
to accrue income over the term of their investment. It also asks for comments on a number of related topics, including the character of
income or loss with respect to these instruments; the relevance of factors such as the nature of the underlying property to which the
instruments are linked; the degree, if any, to which income (including any mandated accruals) realized by non-U.S. investors should be
subject to withholding tax; and whether these instruments are or should be subject to the constructive ownership regime described above.
While the notice requests comments on appropriate transition rules and effective dates, any Treasury regulations or other guidance promulgated
after consideration of these issues could materially and adversely affect the tax consequences of an investment in the notes, possibly
with retroactive effect. You should consult your tax advisor regarding the U.S. federal income tax consequences of an investment in the
notes, including the potential application of the constructive ownership rules, possible alternative treatments and the issues presented
by this notice.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Treasury regulations under Section 871(m) generally impose a withholding
tax on certain &ldquo;dividend equivalents&rdquo; under certain &ldquo;equity linked instruments.&rdquo; A recent IRS notice excludes
from the scope of Section 871(m) instruments issued prior to January 1, 2027 that do not have a &ldquo;delta of one&rdquo; with respect
to underlying securities that could pay U.S.-source dividends for U.S. federal income tax purposes (each an &ldquo;Underlying Security&rdquo;).
Based on our determination that the notes do not have a &ldquo;delta of one&rdquo; within the meaning of the regulations, we expect that
these regulations will not apply to the notes with regard to non-U.S. holders. Our determination is not binding on the IRS, and the IRS
may disagree with this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including
whether you enter into other transactions with respect to an Underlying Security. If necessary, further information regarding the potential
application of Section 871(m) will be provided in the final term sheet for the notes. You should consult your tax advisor regarding the
potential application of Section 871(m) to the notes.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 81%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B">Accelerated Return Notes<SUP>&reg;</SUP></TD><TD STYLE="width: 19%; border-top: #5B862B 1pt solid; font-size: 10pt; color: #5B862B; text-align: right">TS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  > )(# 2(  A$! Q$!_\0
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MU"] ?H*W:ZL3BW55EH>=@<L6'?--IOH<7XN%U_PD>BSPV%W=0VC>;)Y$+/\
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C![GC]?2N_HHI5:O.DK62*H8=4G*5[N3N^GEL@HHHK$Z3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %J M,# 2(  A$! Q$!_\0
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MD^8LSNHR4&> .<CFN2GO?$D_PCG\$Q>"]:34[2T^SSSR0_Z.RHW)B8<RLV
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MNGN#53X<VVH6:>./%6H:9J$5Y>WTKPQ3VLBRR0HI:,+&1D_>P,#G&.U>J44
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M&7X=ZY>SVL'B#QM=ZMH]K,DT=DUC'$[E#E/,E&6?'?UZ\5Z%11UN'2P4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #W)Q6[4%E_QXV__ %R7^53U35G8SB[I,****104444 %%%% !1110 4444
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M>VPF2!#!=H5=V8#;N!(R =Q[@ FM>'5(;J_ABM[BQF@FMOM$;1W(:1UR &5
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M;:VOYK=%9U8LW[ME/.!QG%:MW\/_  S??:UN;"5X;MVDGM_M<PA=R,%_*#[
MW?<!G/.<\UM6VE65I?W5]!#MN;I8TF<NQWA 0O!.!@$].O>E;W;?UM;\]?\
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M_H<]<_[\V7_R/1_PCVJ?]#GKG_?FR_\ D>N@HH Y_P#X1[5/^ASUS_OS9?\
MR/1_PCVJ?]#GKG_?FR_^1ZZ"B@#G_P#A'M4_Z'/7/^_-E_\ (]'_  CVJ?\
M0YZY_P!^;+_Y'KH*X36_$30^,9]+U/Q(?#5C';)+:3;84^V,3\_[R963Y/E&
MT -\Q)R,4=;!YFW_ ,(]JG_0YZY_WYLO_D>C_A'M4_Z'/7/^_-E_\CUAZMKO
MB;P]::!;W$*ZE/=:H+=KFR$8\^#:Q7(=E"R, "<?+PV",@5J77CBSM1=7 T[
M4)M,LYC#=:C&(O)A8$!\@N'8*3@E5(X/7!H_K\O\_O#^OS_R+'_"/:I_T.>N
M?]^;+_Y'H_X1[5/^ASUS_OS9?_(],N?%R)KEYH]EHVIZC=VD<<LWV;R515<$
MJ=TDB#L>.O%8WA/Q?=:MI7AF75%OK>\U)I@H5(/*GVH6R<$LJ@<#&&R.1CJ+
M7^O7_)@]#<_X1[5/^ASUS_OS9?\ R/1_PCVJ?]#GKG_?FR_^1ZI6'Q L+]-/
MN%TW4XK"_N/LL-[+'&(_.RP"$!RXY4C=MVYQS1J7Q L--AOKHZ;J=QIUE*8)
MKZWC0Q"4$ H 7#'#$*6"[0>,\&C^OR_S7WA_7]?<_N+O_"/:I_T.>N?]^;+_
M .1Z/^$>U3_H<]<_[\V7_P CU>UZ/49_#]\NCW/V;43 QMI=JMB0#*Y# C!/
M!X[U@7_BV:7X<6VM:<JC4=0BBAM8V'W;F0A ".?NL23_ +IH_K[P[&C_ ,(]
MJG_0YZY_WYLO_D>C_A'M4_Z'/7/^_-E_\CU%<>*1ISSV<=AJ.L3:="IOY[18
M0(VV[N0[IEB/FVH#C(XY K*G\<1VFN7]XT\ESH<>DVEY"D,:[F,LKKN&<'D;
M>">,4=;(72[-K_A'M4_Z'/7/^_-E_P#(]'_"/:I_T.>N?]^;+_Y'JS>>(]/T
M_5WTZ[9XFCL7OWG; C2)6"G)SG/.>E5--\86U_>V=M-INHV OT9[&6[1 MR
M-QV[78J=OS;7"G&>.#@6NW]?U8>P[_A'M4_Z'/7/^_-E_P#(]'_"/:I_T.>N
M?]^;+_Y'KH** .?_ .$>U3_H<]<_[\V7_P CT?\ "/:I_P!#GKG_ 'YLO_D>
MN@HH Y__ (1[5/\ H<]<_P"_-E_\CT?\(]JG_0YZY_WYLO\ Y'KH** .?_X1
M[5/^ASUS_OS9?_(]:5V&M="G#RR7#Q6S!I9-H:0A>IV@#)Z\ #T J]5/5_\
MD"WW_7O)_P"@FLZO\.7H_P F:4M:D?5?FANBR>;H.G28QOMHVQZ945G>"I$E
M\'::\;JZF,X*G(^\:O>'_P#D6]+_ .O.+_T 5B?#+_DG>D?[DG_HQJZ:L?WD
MWY_^W,PA\$?ZZ(ZRBBBLBPHHHH **** "BBB@ HHHH **** "BBB@#S_ ,-_
M+\9_&X'1[:P8_41D5Z!7G_AW_DM'C3_KTL?_ $ UZ!0 4444 %%%% !1110
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M7**Q>)F5BA+$X)4D=^Q-4Y.3<GU_S)2LE'M_D;=%%%(84444 %%%% !1110
M4444 %%%% !1110!Y_H'R?&KQ@O7?963?3"D5Z!7G^A_\EM\5_\ 8/L_Y&O0
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW\-'V&/_ )Z3?]_#0!O45@_88_\ GI-_W\-'V&/_ )Z3?]_#0!O45@_88_\
MGI-_W\-'V&/_ )Z3?]_#0!O45@_88_\ GI-_W\-0W5LL5M)(DDNY1QES0!TE
M%,B_U*?[HI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9<?\\]OSYZ=J].KSV*UM_P#A?T\WD1>;_8"OOV#.[SMN<^N./IQ22N^5[/\
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M]I&J7>KZYK\NN:M/&L"W#VZP)%"#G8J*2!D\D]\#CKGJ9 YB<1,JR%3M9EW
M'L2,C/TR*3^&W]=1];GGOAKQ!XAU3Q7)X;N[N,2Z$S-J5TJQYOE?/D */N94
M[GQC!  QFO0V^Z?I7'Z9X$_LFXTF]MM3)U*VDE:_NFAR=0$O+AQNX^8*5.3M
MV@<UV#?=/TJ9_ []G_7]?J'VOZ_K^O(Y[P%_R(&@_P#7C%_Z"*O:EK]GI5PL
M%Q#J3NR!P;73;BX7&2.6C1@#QTSGIZBL_P"'[[_A]H#;67_0H^&&#TKI*UG\
M3#^OQ9S_ /PF6E_\^NN?^"*]_P#C-'_"9:7_ ,^NN?\ @BO?_C-=!14 <_\
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MN?O6QX_T9<'G3KWG' ^>WKH*.B^?Y@]_N"BBB@ HHHH **** "BBB@ HHHH
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M9K<EP0R.JA6X)QT/!Y]J4U[KMV?Z6_7_ ( XOWE?R_6_Z=_F<]X6U[4[RU\
M?VM#?P7-W!,,C4 ZW"K ")90%.\MU )!4GG--MOBUJ4UE!J\G@RZCT W'V:?
M4/MB'RV\S9E8\;G7.WGCDD=N9/#FB>)&'@?^T]%^Q-HB3VUQ_I4<@*^2$1QM
M/\1'3DCO4T7A?65^#AT$V>-3WD^1YJ=/M&_[V=OW>>M:2MSM]+_^W+]/ZT,]
M>7S_ . _UL7]:\=ZE:ZY>:;H'A:YUL:<JMJ$T=RD(AW#<%0,#YC;><#'8=ZJ
M77BB?5?!_AWQK;_:+&VCO$DN[99B0UN[-"V_& V,J_(XQ^-5;N?Q'X<\4>(V
M\.6.FZQ:7TB7$Y?44A;3)?+"DS*>2A # #G /M6C\/\ 3DU;X/:=8:@H>.]M
M)$E _B5V;D?@<UFOAOVL_P 7IZ=/ZTM_%;IJOP7X_P!>NIK5U<W?C'0M(M)Y
MHHH_,U"],3%<QH-J(Q'9G;..X0USFI?%._TC4('U'PE/9Z-/<>3%=W5]%%<2
M ,%+K;'YR 2#Q_"0>]:_@71=:M(]0O\ Q BQZI.(K5")%?\ <PIM5LCIN8N^
M.VZO,I_A]XH_L6YTR'P+IK:D+@3SZ]/?I-+>%9 <QAOFC9^"<D#&[.":I?$E
MT_S?Z('=Q;Z_\!_J=Y>^*;GP_KWC>^E\Z\M[!+$Q6K3E57>"&V\$+DG)P.<5
MUE_KHL=?T?3#;[AJ(F)EWX\KRT#=,<YSZC%<EKGA#5M7D\<I'$D7]J6]J+*1
MW&UY(U)((!R/FP.1W[T65MXP\0>*-"U'7- @TJRLX[F*6)+Q)WR\8&\D8 !Z
M #)')/:I5[)?UM+]; ][_P!?9_2XY?B;>OG55\)7G_")B3:=8-S&&VYV^9Y'
MWBF[OG[O/M7H8((R.17@$'PDN+64:0WP_P!/NW63:NO2ZS*L+)G(=K=7#[MO
M! P-W3BO?8T$<:HHP%  JE;E_KL#^(P+M]WQ!TI ,[-,NV8^F9( /Y&NAKGM
M$/\ :>NZEK:G-L56RM&QPZ1EB[@^A=B/<("."*Z&ET0/<**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC5/"N-HQFWFIWV3XL?\ 04\*_P#@/-7>P_ZF/_='\J?0!Y_]D^+'_04\*_\
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M'3<%8!OQSQQ72PPQ6T$<$$210QJ$2-%"JJC@  =!3Z*%HK!UN%%%% !1110
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MN,X)"NT8//60#8.GK0!V5%8VN>+-!\.6$=[J^JV]M;RC,3%MQD&,_*%R6X]
M:C\.>,_#OBU)&T/58;PQC+H R.HSC)5@& ]\4 ;M%<-\2?B19> M*X\N?5YE
MW6MHX8!QN +$@8 'H2,XXKG?%'Q'G/A?P;=:+KD,4NKZA'#<78MPBLB_),0L
MH.U0Y'/; Y]0#UNBN>T3QSX8\1ZC-I^D:S;7=U""6C3/(&,E21AAR.1FJFK?
M$SP9H>I#3M0U^VCNMVQD0-)L;T8J"%Z]R* .LHK"UCQEX>T'0[?6M1U2*/3;
MAE6&XC5I5D+ D;=@)/ )_"HK/QYX6U#7O[#M-;M9M1YQ"C$Y(SD!L;21@\ Y
MH Z*BJ>JZI9:)I=QJ6HSB"SMDWRR%2VT?0 D_A7GG@WXN67B>]\0F::W@BL(
MY)[6%8WW-;QYW3.Y&T9ROR\$<]: /3Z*\F\ _%731X.T^?QAXGMCJMY+(0K(
MJE%#%5W"-0%'RDY;'7K7H>M^)]$\.:>M_J^IV]I;./D=VR9.,_*!DMQZ T :
MU%9'A_Q3H?BJT:YT34H;R)" ^S(9,]-RD C\157QSX@F\*^"=5UJW@\Z>UBS
M&FW<-S,%!(R/E!8$^P- '0T5Y'I-[\1M2\,V?BG1_$NG:Z\Z1R/HBV<42)N(
MW)YVX$,O.<GL>O%7_B#\6;?PDMGIT'DQZU.8S<17"NZV4;C)=MG#D?W5;)H
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M+6]WHNHM&[06MQNE*C)'*G_V4TGBB02ZUX8D7.'N-PS[M'77T5<J',Y:[V_
M;A>YR6H?\E+TK_KU;^4M&H?\E+TK_KU;^4M=;10Z%[Z];AR?F<6;[_A%O$>I
M/<VMQ+;W[J\<D2[OFY^7DCN3Q[4WP_=27OCW4;B6W>W9[7(C?[P'[O&?<C!_
M&M*^TC7DO9KC2=8V),V3#<98)_NY#8'L /TJSH>AS:?<W-]?7?VJ]N,!W"X
M [#_ #V%81IU/:)6=D[]//K\R$G?R-NBBBO0-@JO?_\ 'C+]*L57O_\ CQE^
ME &U#_J8_P#='\J?3(?]3'_NC^5/H **** "BBB@ HHHH **** ,7Q?J9T7P
M=K.I+C?;6<LB9.,L%.T?GBO$=3LY;+]G_P )^'867[3K][$"3V$CF0''?'[L
M5] WEE:ZA:26E[;0W-M(,/#-&'1AUY4\&JTF@Z/-]A\W2;%_[/Q]BW6Z'[-C
M&/+X^3&U>F.@]* +EO EM;101C"1($4>@ P*\BT76=-O/C_XBO=2U*TM6L;>
M/3+&*XE6-I68C=M#'+'<&'']\5[#6=<Z!HU[?Q7]UI%A/>0L&CN);9&D1@<@
MAB,@@@4 >9_#>.WU3QOXZ\9W4<3>7>M:6\A&2B1CYB#VRH2N$>#5YO@#K6N6
MBX;6-9>ZO!&#E;?)4@8[;P,]L$U]$V6B:3IMC+8V.EV5K9S$F6W@MT2-R1@Y
M4#!R  <]A4UGI]EIUBEE96=O;6B A8((E2-<DDX4# R23^- 'AMSX?A\6+HV
MAS?%RQOE65);*UL=+A61&53C!B;*$+GKTQDCBO>)I4@ADFD.$C4LQ] !DU4L
M=%TK2Y)9-/TRRM'E8M(UO L9<GJ20!DU<DCCFB>*5%>-U*LC#(8'J".XH ^2
M]!MOAQX@BOM6\9>(]0L-5N[V6;[/:1LRJC'(R?);)R6[],<5Z#>6_A;PK\!_
M$-UX/OKJ^M-2D$/VB[4JS%BL; 91. -W;KGFO5?^$$\'_P#0J:'_ ."Z'_XF
MKK^'-#DTI-*?1=.;3HVWI:&U0Q*V2<A,8!R3V[F@#R+QYHB:#\'_  UX0LXH
MDN=3N[:VE8+C,A^9G]3\^/P-6I[_ $_3?VA2OB*>VLM/L-'5=+DNY52,-\GS
M L<*?]:.WW:];N]+T_4)K::]L;6YEM7\RW>:%7:%^#N0D?*>!R/2DOM)TW4V
MA;4-/M+MH'#Q&XA60QL.ZY!P?<4 >/\ @B33=6^-_C+Q/8NATZTM45&1<*Y9
M4!<'T/E.<]]V?KB6%]+9?L_>*O$,@47/B"_E8#/02.(R,]\?O#7O$>AZ1%]N
M\O2[%/MXQ>;;=!]I&",2<?/PQZYZGUJ-_#FAR:5'I3Z-IS:=&VY+1K5#"IR3
MD)C .23T[F@#R+QYHB:#\'_#7A"SBB2YU.[MK:5@N,R'YF?U/SX_ U8N+W3M
M-_:&QXCGMK*PL-'5=*DNI52,-\OS G@'F4?\!^E>NW>EZ?J$UM->V-K<RVK^
M9;O-"KM"_!W(2/E/ Y'I7%>(?#OC2[U!I+.7PMJUJLYFMH];L6WVO)(VLG4C
M. < X [Y) .7\ G3_$?QX\7>(],E26Q@@CAC9%^5W8(I<'T)B?GOG->S2(LL
M;1N,JP*D>H-<IX%\&R>%8M3N;Z\6]U;5+DW-W<)'L7/.U%'7:,G'UKK: /F3
MPU'?:Y,/A*HD^PV>LSRWT_ S:Q./D]<E\\C&"5]Z]*^(OB;^RO$_AWPU';:+
M:03J9UU/6(0\%MLSM" D88%1SD?>7\/1;?2M.M+ZXOK;3[6&[N?]?/'"JR2_
M[S 9;\:=?:98:I$L6H6-M=QJP94N(ED (Z$ @\T >'^&KY=;^/,VI7>MVFLC
M1M(DD6\M(1#%Q\I PS;L"9N<_P A6;;7EQ9_L]>)=>/_ !\^(-2D=B!]U7D"
M,/?H_/O7O7_"/:)]HN+C^Q]/\^YA-O/)]F3=+%@#8QQEEP ,'C 'I4T.DZ;;
M:8-,@T^TBL "!:I"JQ8)R1L QR23TZF@#Q/QUJ^D3?#+P[X'T'4K>_GNY;2R
M>6W<2(FW'+%<@,6V_+G/4]J/%$.HVGQL2.;Q/;>&K.#2E72[VYMDECV@*&0"
M0A%8G><@YP .]>S#P]HHBM(AH^GB.S<26J_9DQ XQAD&/E/ Y&.E3ZAI>GZM
M;_9]2L+6]@SGR[F%9%S]&!% 'G7PV\/0?\)7K7BF/QHGB*:Y06MRUO9B"+>-
MA!^4E6(50.!_$?6G?'&:2?PCI^@PD"76=3@M 3_",[LX[\A?SKTJ"WAM85AM
MXHXHEX5(U"J/H!5>\TG3=0N+6XO=/M+F>T??;230J[0MD'*$C*G*@Y'H/2@#
MR_Q_8Z$_C#2IK+QI;>'/$NE6I6#[6H,/E8('W\(#\YYY)&>#MXUOA1XAN_$T
M6LW6H:9IJW=O=F ZG81@1WV."P/5L!5YZ$%?2NWU+0](UE475-+L;X)RHNK=
M)=OTW XZFK=O;P6L"06\,<,*#"QQJ%51[ =* /-/CC-)<>%--T&%@LNLZG!:
MY/.!G.<=_F"UR_BJ+4;;XW*LWB>V\-6D.EJ-+O;JW26/:-H9!YA"ABV\Y!S@
M =Z]KO-)TW4+BUN+W3[2YGM'WVTDT*NT+9!RA(RIRH.1Z#TI=0TO3]6M_L^I
M6%K>P9SY=S"LBY^C B@#RCPOH>D17/BKQ7J/CP:W;7=JUCJ,]M:?9HUR%&[*
M$@L%Q@J.-Q/>N6M-8D\&V6CZ9H6O:+XR\/WEX@ATB2!/M4.YBX.WJ#GN^,-C
M@<X^AHK6WAMQ;Q011P ;?+1 %QZ8Z52LO#NB:;=O=V.C:?:W,A)>:"U1';/7
M+ 9- 'FWQ"L]"F\9Z9<67C.U\-^)=,MB(!=(/(\H@X'SX13\Y'?(SP=O&K\*
M/$-WXFBUFZU#3--6[M[LP'4[",".^QP6!ZM@*O/0@KZ5V^I:'I&LJBZII=C?
M!.5%U;I+M^FX''4U;M[>"U@2"WACAA086.-0JJ/8#I0!Y/\ %?4+2?Q[X(T3
M4+N"TT];HZA<RSL$3Y/N L>!G#C_ ($*;KHL_&?QS\-V2M;WFF:;IS:B2I$B
M2%S\N,<$9$1]Z]1U'2-,UB(1:GIUI>Q@Y"7,"R ?@P-,L]!T?3KPW=EI-C;7
M)B6 S06Z(YC  ";@,[0%4 =/E'I0!YG9W37/QN\7:VMN9X_#^DK;QPQ ;Y6*
M[\#WR'7\JXR]\;3:C\,]6U$:YX8TDZD)5?1;*R5KF3<3'\YWY!*@'?MZ<^@K
MZ$M=+T^QN;FYM+&UM[BZ8-<2Q0JC3$9P7(&6/)Z^IJM)X:T&5+E)-$TUTNB#
M<*UHA$Q!!&_CYL$ \^@H \/NM(BOO#_PF\&A%-M>_P#$QN5))RI'F,/Q#R?2
MNNUB%=3_ &@/#>FPQQ);:+ILEV55<8+94  =,'8:]'31-)CN;2Y32[);BSB\
MFUE6W0-!'C&U#C*K@D8&!@U(FEZ?'J<FII8VJZA(GEO=+"HE9./E+XR1P.,]
MA0!E>.=7?0? VM:G%Q+!:.8SC.'(POZD5Y)'J^EZ'^S/-9Z=J5G=7LELJW,4
M4ZL\;7#\AP#D$*6'/]VO>7C26-HY$5T8896&01[BL8^#?"YBDB/AO1S'*XDD
M3[#%AW&0&(V\D;FP?]H^M 'EGCO15T+X0>&?!]I'#'<:I=VMK*P3&9#\S/CN
M=^/P-5?%,6HVWQM1)O$]MX:M(=+5=+O;FV26+:-H9 )"$5BV\Y!S@ =Z]MN]
M+T_4)K::]L;6YEM7\RW>:%7:%^#N0D?*>!R/2C4-+T_5K?[/J5A:WL&<^7<P
MK(N?HP(H \Z^&WAZ#_A*]:\4Q^-$\137*"UN6M[,01;QL(/RDJQ"J!P/XCZU
MT/C_ ,4V_AFQL!J&DK?:3J%TMG>RR/B.WC?@LXVG<,9XXZ=:ZN"WAM85AMXH
MXHEX5(U"J/H!2RPQ7$3131I)&PPR.H((]P: /GGQ#I>A>&_$>D:G\+]>CEU.
M\O4A?2[*\$T;H0Q)8*20O&"#D#.1C%=3XDUC3IOV@-(BU;4;6QL=$T]YU>ZD
M6)6FDXQN8@'@H?\ @)KT_3O#^C:.6.EZ186);[QM;9(L_7:!1J6@:-K)4ZII
M-A?%/NFZMDEV_3<#0!Y7=>-Y+[X@Z]"-0\.>&?[* @2\U*V62ZN5.22AWKE3
MM!P.Q7\.*T341:_!_P"(7B+S!-=:OJ/V0R[?+\P,02=@.%XF<X'T[5]'2Z1I
ML]]'?3:=:27<8PD[PJ9$'H&(R.@JG_PB?AO^SO[._P"$?TK[#YOG_9OL4?E^
M9C;OVXQNQQGKB@#R[QEHUAX"^"+^1:0'5[BSAT^6],0,C!\;UW=0N <#..!4
M'CFXTV3X1^'?"FA:E9WPO+NTTQIK:99 K !B3M/7<%...M>UW%M!=0-!<01S
M0L,-'(@92/<'BLR'PEX;MS;^1X?TJ+[/*9X-EE&OE2?+\ZX'RM\J\CGY1Z"@
M#SKQ#IUOX@^.OAO0Y(8Y+#1=.:\:-AD$YPH(]B(S4*O>:C\8_&FJ:="LD^B:
M)]DM(UZO,R;E&>@^8.*]832]/CU.34TL;5=0D3RWNEA42LG'RE\9(X'&>PJE
M>:&L=KJ#Z#]ETG5+PJ[WL=HC&1U.?W@Q\^<L.3G#'!!YH \2\,^(_"NF?L]Z
MI;W&H6?]L7T-TL]NT@:>2=RRQL5^\<#8<]!C->F_"#2_[*^%NAQ$Y>>(W+'&
M/]8Q<?D"!^%<]J/P_P#&.OQW>G:C/X5L;*]*?;+_ $RSD2\N54@X;/R\X]3^
M1KU*RLX-/L;>RMD$=O;Q+%$@Z*JC 'Y"@">BBB@#*U3_ )"%A_VT_D**-4_Y
M"%A_VT_D** "LNWUCS=>N=*E@\J2-!)&^_/FKW/3C_\ 76I7,>*E;3[FPUZ%
M26MI!'-M[QM_^O'XUC6DX1YETW]"9.RN;6KZE'I.F37LB[A&.$SC<3P!4UG-
M)<V4,\L/DO(@8Q[L[<]LUS>MN-;U_3=(C.^V4"ZN".A7^$?Y_O"GZ^FG-JJ#
M5;^22 QX33XE;)/]X[3D]#VK-U7>36RT^?4GFU;.HK)\/:W_ &]I\EU]G\C9
M*8]N_=G !SG ]:P?"]T%\47]C;+<16 A#QP7&[<F-HX!/ .XGZ8J#PQ_R(.L
M_P#;?_T4M0L0Y236WO?@+GN_O.[HKDM(_P"2:2?]>MQ_-ZHQZE-IGPUM9+<L
MLLCM$' ^[EW)/Y#'XU?UE))M=+CY_P CNZQM8\10Z7.EK';37=XZ[EAA&3CW
M]/R-<E#'/IUW;W6G6GB R^:#<"Y@.R1>_ YS]<UWTL=I;/+?O%$DBQDO-L&[
M:!DY/7'%$:LJL7;1KY_Y I.2[&1IGBA;N\CL[VPN;"ZDSY:2J<-CT) _E6_7
M)V"3^*=2MM7N(Q#86CL;5,Y:1L_>/IR!^7XUUE70E*4;MW71]QP;:U"BBBMR
MPHHHH **** "BBB@ JO?_P#'C+]*L57O_P#CQE^E &U#_J8_]T?RI],A_P!3
M'_NC^5/H **** "BBB@ HHHH **** (;LSK9SM:A#<"-C$'!*[L<9 (R,^]<
MK\,_&$WC;P5#K%X+:.[$LD5PEN"$1E.0,$DCY2IY/>NPKYQFUN_\,ZKXU\ Z
M4K-JFL:JHL&0$;%G&78D=-J;!GWST% 'K7@KQ??>+;[7;[RK6/P]:W!M["<*
MPDGVCYW+%MI3T('?GI71V.OZ-JEQ+;Z?JUA=SQ'$D5O<I(R?4 DCH?RKSWQ?
M_8O@KP/H/@K^R&U3^T9$LH+<SM;I(^1N>21>F6<'W)]JY"[TJ6/XR^"]+_LG
M0M%N(I'N6CT1CO9%&[$IV+G(C8=\@MZT >GMXMU"3XNKX3MX[4V$>F?;+B1D
M8RA]Q  .[ '*=1ZUTUIK.EZA:S75EJ5G<V\#,LTL,ZND9 R0Q!P" 03FO(=%
MU5H]5^*WC55&+?-I;$GDM"A7\CB.JT-S:^#OV9!'--&+K5;601H" TC3D]!W
MPAY_W: /:;;5=.O=/&H6E_:SV1SBXBF5HS@X/S XX(Q2:=J^FZQ"9M,U&TO8
M@<%[:99%!^JDUX+KFG:W:S_#KP3:V^FK;/8_:&AU M]DN+K#,ZR!.3@\CU9Q
M73^$O!>OZ=\3(]9N)_">G0PVK0WFG:%O02*0VUFC8<'<5.[(^Z/>@#U^J=YJ
MVFZ?<6MO>ZA:6T]V^RVCFF5&F;(&$!.6.6 P/4>M.T_4[#5K7[5IM];7MON*
M^;;2K(F1U&5)&:\W^,[PV<G@S4IY!%%:Z] SR$X"+]XG/T7/X4 >D7&IV%G=
MVUI<WUM!<W1(MX9955YB.NQ2<MC(Z5#?:]H^F7,5M?ZM8VD\QQ%%<7*1LY]@
M3D]1T]:\T\/-?>);W7OB7)9M,;:VG@\/6KC&8T5OW@ST+GCIW/48JE\.=&\*
MZC\,YO%/BFWLM0O;MYYK^\OE61T(=E !/W?E (QCK]* /8;J^M+&S>\O+J"W
MM4 9YYI B*#W+'@=:KW&MZ39Z;'J5SJEE!82A3'=2W"+$X894AR<'(Z<\U\Z
MK-K$GP!T70[ML'6=86VLS)G*V^0P)SV\P<=L$5W7Q2^Q:IKG@GP-;F*4M?QS
MSP9!"0QC;\P]U+X'L: /7P00"#D'O5%-:TJ32?[634[)M- )^V"X4PX!P3OS
MMZC'7K5ZOFS5;R;6?#.K^!K$R1P:)<:K?:BZC $<3R/"G3!#.1_WS0!]#2ZS
MI<%K:W,VI6<=O>,JVTKSJ$G+#*A"3AB1R,=:YVP\2:M/XT\1VMP-+_L+2X%:
M-X)E>XWE03Y@$A*#A\ H,\<\<\!\-YF\;7FBZA<*PT3PGIL,$0;(66\\I=[X
M_P!@#'Y'O63I6H&T^"/CGQ0\9637[Z<1CN4D8)S]"\E '4K\4-<C^";^-+BV
MTX:C)/Y=O$L;B(CS0AR-^2<!SP?2O5;-IWLK=KD(+@QJ90@(7=CG .>,UXMX
MBTMX]-^%?@DJID>XBN;@?PCRE!?\][X^E>VR2+%$\CG"H"Q/H!0!QWA[Q;J&
MM_$3Q1HACM1IFD"%8W1&\UG=<G<=V, A^@':NBBU_1I]2;38=7L)+]/O6J7*
M&5>G5 <]QV[U\]_VIJUC\%?$7B6Q#Q2^(-<=I)8VPT4#$Y)/NX*\?WJZGXF^
M%_"/AOX6Q)H]A9)JC/;IIUS"@^TS/O4E@X^9B5W=^_TH ]DO;^STZV:YOKN"
MU@7[TL\@11]2>*9I^JZ=JUOY^FW]K>PYQYEM,LB_FI([5Y5XN\+:WX@OO#-W
M%?Z)?ZYI]@/M>A:FP>&5]GSR!.IY8=<#[IR.^5IFO6L'@7QOJ_A_PI%H7B/3
M_P#1KL6KYC!R%9D(^7Y K-A1U&?XLD ]F;7-)34AIKZI9+?D9%J;A!*1_N9S
M^E7Z^<+?P)K^L_#[3V$?@.TBOHXIHM4D,R7Q<D-\TI!^<G@@9[@5[U!++H7A
M2*;5K@W$UA8AKN:-"3(R)EV '7)!.* )+W7]&TRZBM;_ %>PM;B4XCBGN4C=
MS[ G)ZC\ZP_B1XLN/!W@>[UJP2WEND>)(5G!9&+. <@$$_+N/!KR+5IK;5OA
MYK7BRU\'>';2RU#SMMYJ%VT]X7),>Y,H=KY&0 P&>?<VIK26X\+?"3PJTCS&
M\N$U"0RMG$:_/M^@21@!Z*!0!Z/K/B_5].\9>#O#T,5DTNK)(]^7C8E BACY
M?S<='ZY[5W->6Z9G6_VB-8N\ PZ)I<=H">N]R&X_!G%7/C?K&IZ-\-KF33#(
MCSSI;S31MM,439R?Q("_\"H [6+7]&GU)M-AU>PDOT^]:I<H95Z=4!SW';O4
M]YJ=AI\EO'>WUM;/<R"*!9I50RN>BJ"?F/L*\=^)OA?PCX;^%L2:/862:HSV
MZ:=<PH/M,S[U)8./F8E=W?O]*?KEG?\ B?XG>"-!U"0I=:;I1O=0EB;&'=0K
M[3U!W(.>V<]J /8[>[MKQ&>VN(IU1RC&)PP5AU!QW'I5;4M<TG1E1M4U2RL5
M<X4W5PD0;Z;B,TS0M TSPSI$6EZ1:BVLXBQ6/>S<DDDY8DGD]S7C_P#:=CXL
M;Q%XJT_P=H$MG;.T,U_K]R[,WEKG(B*-LX8<#!/3MP >WQRQS1K)$ZR1L,JR
MG((]C4%UJ5C8RV\5Y>VUO)</L@2:54,K>B@GD^PKSOX!VDEM\+;:5Y9'6YN9
MI45VR$ ;9A?090GZDUG>-5TWQ)\<_#'A[5/+-G:6<MP8W;B>1\XC(],1J2/X
MAD8YH ]3L=6TW4VF73]0M+MH'*2BWF60QL.S8)P?8U'?:]H^F7,5M?ZM8VD\
MQQ%%<7*1LY]@3D]1T]:\<O;5-'^.%U-X+T^VCCT[09GOK:T141Y=LA1" ,!B
MWD^G2K?PYT;PKJ/PSF\4^*;>RU"]NWGFO[R^59'0AV4 $_=^4 C&.OTH ]AN
M;VULK-[RZN88+6-=SS2R!44>I8\ 5BZ[XW\/Z!HLNIW&J6<B+!Y\44=S'OG!
M!*^6"?FW <8ZUX4L^L']G73M'N@S2ZQJR6FGAR01#N#+G/;>AQCL170_%#P=
MHNA^&K#3+*UCDUK7K^VM'O)V+,-@P&4'A ,JN%QP<4 =G/\ $.XOOA>_B;1C
MHXU%F0+;7-_'Y419Q\DCED ?RSG:2,$XY[]>=5ATO1;:ZU^]LK*0Q)Y\DDBQ
M1"0@9 +,<#/3D_4UYC\0M$TRWU3P-X-TK3[:VANM56\F2")45EB4!F8 <L5)
MY/7'6D\.V5IXR^+WC!_%-K%='262WL+*[Q)&D1+9<(>#D*K=/XZ /6[2\M;^
MV2YL[F&YMY!E)87#JP]01P:HKXGT!K5KI=<TPVRR^2TPNX]@DX^0G.-W(XZ\
MBO(O#M]'H7C+XDZCH,<2>&+&RWK';C$7VE8QPF/EZB3./5>U8]IX8TC0/V<K
MG6K_ $RWN=2O8C)%+*@=HC*X1"A/W?EVL<<T ?1*LKH&5@RL,@@Y!%0W=Y:V
M%L]S>7,-M;QC+RS.$51ZDG@5D>"=/DTGP-H=A-_KH;&)9!G.&VC(_/->?ZG#
M'XJ^/QT/Q#$)-)T[3?M%E:3,#%<2'9ERO<_,XP<_ZN@#U"WUO2;S3I-1MM3L
MI[&)6:2YBN$:-%7.XE@< #!SZ8KSR#XE:GXA^(%SH/AB7PX]E:%09KN[8R7F
M5W-Y&S@[<-GJ..HS61;V&FP?'F>R\/V=E'H::.R:W;PQ 0'._P"5E VYYCX/
M;=[U9^!NAZ=<Z3J'BAM*LXY[O4IGLG$*[X(L;=J''RCEQ@<8H ]'\3>)M,\)
MZ+/J>IW$<:1HQCB,BJ\S 9V(&(RQ]*XO5_BDT7PED\7Z:FGM>ET1;4S>>L19
MQ\LFTJ=_EG)'&">XZUOCL(;OPWI&CB"W>^U/4HK:WED4%H03\S*>HYV@XQP:
MS/B;X>TPW7@OP+I>GV]K;7^H_:+A;>-8@5C4*S':.6*LW/7Y: /5K#6+2=XK
M&:_LFU40J\]M%*-ZG')V9+ 9SUJ74-9TO2?+_M+4K.S\UML?VF=8]Y]!N(R:
M\IU#0=*B^//A?3=&TNULEL+*6^NI((PADSN5=Q'+$$#D_P!XURWA>Q\4>,9_
M$6M7&G^#[N<7SP7"^(5DDEM0H&$3;\JH,X!X.0: /HI'61%=&#(PR&4Y!%.K
MB/A3X=U+PQX)CT[4=3M-0_?/);R6DADC2(@856(&>0Q_'':NWH **** "BBB
M@#*U3_D(6'_;3^0HHU3_ )"%A_VT_D** "J]]:)?V$]I)]R9"A/IGO5BBDTF
MK,#G/"WAV?1%N)+R6.6XEVJ"C$@(!P.0/\@4^\T:_CU]M7TR>V\V2,121W(8
MJ!QR,?0<<=ZZ"BLE0@H*"Z$\BM8Y[3M#O[3Q+-JMQ<PS^?!LDVJ5(;(Q@<\8
M4#K2^'= ETS0[G3[UHI//=B?*)(VLH7N!Z&N@HHC0A%W7G^.X*"1QL/A;7(;
M";31J\8L=C"-%3!8D$X)QD#/7!/&:T;?PVS>$$T6[D02 ,?,CR0K;RP(SC/6
MNAHJ8X:G'[K;]!*"1S%KHFOFYB6^ULM:0L&581M=P.S$ <?B:Z"^BDGT^YAB
MV>9)$RIY@RN2"!D8.1^!J>BM(THQ32Z^8U%(H:-:7%CI,%M=& S)NW&! J<L
M2,  #H1VJ_115Q2BDD-*P4444QA1110 4444 %%%% !5>_\ ^/&7Z58JO?\
M_'C+]* -J'_4Q_[H_E3Z9#_J8_\ ='\J?0 4444 %%%% !1110 4444 %89\
M'^'SXK_X2@Z;&=:V;/M6YLXV[<[<[<[>,XSCC-;E91\3^'UA28ZYI@B>8P(Y
MNX]K2#J@.>6]NM !KWAO1_%%A]AUJPBO+<'<JOD%3C&588(.#U!K+T[X<^$=
M(UFTU?3M$AM;ZT0QPRQ.ZX!# Y7.&.&(RP)Z<\#&_?ZGI^E6GVO4;ZVL[;('
MG7$JQID]!N8@5@>-/$TVC>&-0N]$N-*FU.V>-!'>W21QJ689#EG4 [=Q +#.
M._2@"YI?@WP_HVCWFDV6G*+&]D:2YBFD>;S68 ,6+DDY '>LK_A5/@<:9+IZ
M^'K=;>9P\FV20.Q!R!O#;L9[9Q[5O6^L6]NMA9:KJ%A#K$]N)&MA*J,[!<N4
M0L25!#=S@#K5JRU.PU-)'L+VVNUC8H[02K(%8=0<'@^U %37?#6B^)K 66LZ
M=!>6Z\JKC!0XQE6&"IQW!%4;+P=I'A[1;NR\-Z39VCW$8C<LS*7'3YG&7. 6
M(YZ]QG-:CZWI,>I+IKZI9+?L,BU-P@E(]=F<_I6'XZUW6=%M-,301I;7MY?)
M;E=0F5!L(.2@,B%VSM^4$DYZ4 7?!OABW\'>%;+0[>4S"W4EY2,>8[$EFQVY
M/ [#%<=\2/#'B/Q_J=EX>&FPVGA^"Y2ZDU7[4K.X"E2BQXRK?.W7(. <CI7H
M$^N:1:SW$%QJEE#-;1^;/')<(K1)_>8$_*/<\59M+RUO[5+JSN8;FWD&4EA<
M.C#U!'!H ;8V5MIMA;V-G$L5M;QK'%&HX50, 5S,_P +_!-SJK:E-X<LFN6^
M]P0C'.23&#L)]\9K<A\0:+<ZBVG0:QI\M\OWK9+E&E'U4'/<?G7/>)?%NH:9
MX_\ "WARPCM735#,UTTR,61$ (V88 ' ?J#VH W-<\+:'XDTQ-.U?38;FTC(
M,<9ROEX&/E*X*\<<&J=GX"\+:=J6GZA9:-!;W.GJZVS1%E";@0Q*@X8D$\L"
M?RKHZS8?$&BW.HMIT&L:?+?+]ZV2Y1I1]5!SW'YT :58B^$-!5]:==/4-K:E
M-0;S'S,I4J1G/R\,?NXZUH3ZKIUK>PV5Q?VL-W,K/%!),JR2*H))52<D  DX
M]*9;ZUI5W;37-MJ=G-;PDK++'.K*A'4,0<#\: *NF>%M&T;PZ^@Z=9FWTUU=
M&B25]V'SN^?.[/)YSD=L8JC-\/O"\_A:W\,R:83H]O(98[87,HPQ+')8-N/+
M$X)(Z>@QO65_9ZE:K<V%W!=6[?=E@D#H?H0<56BU_1I]2;38=7L)+]/O6J7*
M&5>G5 <]QV[T 0W/AC1[SQ'9:_/:%]3L8S%;2^:X$:D,#A =O1CR1GIZ#&C=
MVL-]93VEPK-#/&T4@5RI*L,'!!!'!Z@YJ*\U33]/EMHKV_M;:2Y?RX$FF5#*
M_ VJ"?F/(X'K1-JFGV^H0:?-?VL=[< M#;/,HDD SDJI.3C!Z>E %/3_  OH
MFF>'%\/VNG1#20&7[++F52&8L<[R2>23S6;H_P ./!^@:A]OTW0;6&ZWEUE.
MYRA/]W<3M_#%:[>(M$4W@;6-/!LCBZS=)^X//#\_+T/7'0U5U_Q=HWAWP])K
M5W>P-;B-GA"3)FX(&=L>3AB<=!0!6\1?#_PKXKN%N=:T>&YN% 'FAWC<@9P"
MR$$CGH:U-*T#2=$TS^S=-T^WMK,YS"B<-G@Y]<^]4?!OB>#Q=X;M]6B-LKRY
MWP0W E,'.55R.C[2I(P,9_&M'4M;TG1D1]4U.RL5<X5KJX2(,?0;B,T 85C\
M,_!>FZK_ &G:>';..[WAU8@LJ,.A522JD>P%=4RJZ%64,K#!!&016?J6O:3I
M&FC4;_4;2WM6X2669561L$A5)."2 >!Z5Q/PW\<:_P".I)-0E308=*!(-K!<
M.]Y >0OF#[N&*G!XX'2@#3D^$O@.1+E&\-6@%P07VLZD8(/R$-E.G\.,\^IK
M6B\%Z!#J>DZBEB1=:1;"TL6,\A$,04KC:6P3@D9()Z<\"M*35M-AU2'2Y=0M
M$U"9-\5HTRB5UYY5,Y(^5N0.Q]*<=3L%U-=-:^MA?M'YJVIE7S2G3<$SG'!Y
MQ0!3TKPSI&BZGJ>I6%J8KS4Y!)=RM,[F1@21PQ(4#<>!@?D*OWEG;:A9RVEY
M;Q7%M*NV2*50RL/0@]:JRZ_HT&I+ILVKV$=^_P!VU>Y02MUZ(3GL>W:IM1U3
M3](MOM.IWUK96^X+YMS,L:Y/098@9H P='^''@_0-0^WZ;H-K#=;RZRG<Y0G
M^[N)V_ABM*'PQI$'B>?Q)':L-6GA$$EP9G.8QM^4*3M'W1T [^IJY>:II^GO
M;I>W]K;/<N(X%FF5#*YZ*N3\QY' ]:9+K6E07DUG+J=E'=0Q>=+"\ZATCX^=
MESD+R.3QS0!>KDKKX8>"KV^NKVX\.V;SW2LLK?, =V<D '"MR?F&#GG-=7'(
MDL:R1NKQN RLIR&!Z$&LQ?$^@-:M=+KFF&V67R6F%W'L$G'R$YQNY''7D4 2
MZ)HFG>'-'@TG2;?[/8P;O+BWL^W<Q8\L23R2>37 Z;X%EUKX@^,-4\4Z+')I
MUXL-O8B=TDWQIP2NUB4Y16['GUS7I33PI 9WE180N[S"P"X]<^E5=-UO2=91
MWTO4[*^5#AFM;A)0I]#M)Q0!7T#PSHOA>S-IHNG0V<+$%O+!+.1W9CDM^)K'
MG^%_@FYU5M2F\.637+?>X(1CG))C!V$^^,U5F^)VC?\ "?6OA:VN;.3>A:>\
M:[01HV2HB7D[I"V!MXQGOTKJ;O6])L+N*TO-4LK:YF_U4,UPB._T4G)_"@"M
MJOA71=;GTR:_LO-;2Y1-9A9718G!!!VJ0#C:,9!_4TOB#POHGBJS6TUO3HKR
M%"2@<D%">I5@01^!K3FN(;:%IIYHXHE&6=V"J![DU4TW7-(UE7;2]4L;X)PQ
MM;A)=OUVDXZB@#'TWX>>%M(O=,N['3#%-IB.EF3<RL(@Y8M\I8@D[VY()Z>@
MQ)X@\!>%O%%TEUK.C6]S<)C$N61SCH"RD%A['(KHZ* ,9O"FA-X<E\/KIL,.
ME3*5DMH,Q!@3D\J0>>_/-1ZCX.T'5?#5OX=O;'S-*MEC6*W$TBX"#"C<&#'
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MKJ" W_ @:ZBB@"*VMH+.UBMK6&.&")0D<4:A511P  .@J6BB@ HHHH ****
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M9W3.\Z^=(S.SC#$NS%LD <YH ^?[:^U'1_@7KNM:1";2/6=:91Y!V?9[8\<
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MM:3VNCVK6\4\QGE#3/*7D( +$N2>@'>@!?$6H)H/A/4]05,)96<DBJO'W4)
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MUL_S:F3:?J4T31LUH PP<%O\*VZ* &HI6-5/4 "G444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V 88# 2(  A$! Q$!_\0
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MD:/[9T__ )^E_(U>HH H_P!LZ?\ \_2_D:/[9T__ )^E_(U>HH H_P!LZ?\
M\_2_D:/[9T__ )^E_(U>HH H_P!LZ?\ \_2_D:/[9T__ )^E_(U>HH H_P!L
MZ?\ \_2_D:/[9T__ )^E_(U>HH H_P!LZ?\ \_2_D:0ZUIP!)ND '4X-6KFY
MAL[=Y[B01Q)]YCT':J@^UO!<SSDQ*T15;?@[,;OFW#KD8X[4 7D=9$5T8,K
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MW=SN4'.#YS\9[UJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 5%=?\>DW_7-OY5+45U_QZ3?]<V_E0!'IW_(,M/^N*?^@BBC3O\
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MSM3;H7E?S+B3!E<9VEL ':"3M''2K-%% !1110 4444 %%%% !1110 4444
M%177_'I-_P!<V_E4M177_'I-_P!<V_E0!'IW_(,M/^N*?^@BBC3O^09:?]<4
M_P#0110!9KG_ !C<ZQ!X?N4T2QGN;J6)U62"55:$[3A@#]XY[#FN@K/UQ[Z/
M0=0?3%W7ZV[FW&,Y?!V_K0!SDUWXNU.RM;./19M-<R0F6\>]C;"JP+_*O)W
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M@^7_ *_+G_T<]:=97AYUDTQW7.UKNY(R"#_KG['D5JT %%%% !1110 4444
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M%% !1110 5%=?\>DW_7-OY5+45U_QZ3?]<V_E0!'IW_(,M/^N*?^@BBC3O\
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MX[5RX6[E1!%\I(/1B>H(Z5-%XJL9M36S"3!'N7M([@@>6\R ED'.>QYQC@T
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M4+%[]K-;J W:CF(.-X'TZT <=HNM7\>L6>GIM$1O+BUDL0@W6\,8.R0GK\V
M23P=_%=T1D$ X/J.U1H\#SRA#&9DP),8W#C(!J6@#*\/*5TR16<N1=W(+-C)
M_?/SQQ6K69H/_(/E_P"ORY_]'/6G0 4444 %%%% !1110 4444 %<O?ZA=:_
M>R:1H\ICMXSMO+Y>B>J(>[>_:DOK^Y\17DFDZ1*8K2,[;R^7MZI&>Y]3VKH+
M"PMM,LH[2TB$<,8P%'\SZFL&W5=EMW[^2_5_<1\6VPFGZ?:Z791VEG$(X4'
M'4GN2>YJU116R22LBPHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_(/E_P"ORY_]'/6G65X>W_V8_F;=_P!KN=VWIGSGZ9K49E1&=V"JHR23@ 4
M#,J*68A5 R23@ 5R<LT_C*Y:VMG>'0HVQ-.O#71'\*G^[ZGO2223^,[AH(&>
M'0(VQ)*.&NR/X1_L>_>NJ@@BMH$AAC6.)!M5%& !7/\ Q?\ #^?_  /S]"/B
M] @@BM8$@@C6.*,;511@ 5)11706%%%% !1110 4444 %%%% !1110 4444
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M?CL">M6*Y/0]>M8[I+5XY6DO+J6'[:0-LUP@.]0,Y &T@9[+75DX4G!.!T%
M&7HCI%ID\DC!46[N2S$X 'G/6*SS^-;@I&7A\/QM\SC(:\([#T3^=9,4LVKS
MS6%_!>VFDPW<SNBVTC-=,968#*J0%&>>:["+6=.@B2**&[2-!M55L)@ /^^*
MP:=1V?P_G_P/S]"/B]#2AACMX4AA18XT&U548 %/K*_X2'3_ #!'_I>\C<%^
MQ39QZ_<I_P#;UE_<O?\ P!F_^(K<LTJ*RI/$.GQ(7D^UHHZEK*8#_P! I_\
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MI]O+QO K$L067((R3R<5>\+V!\V^UJ?4K6_NM0*!WL\>2BH"%53DYQD\GK0
MFLZ<;O6&DL=;@L;T6P\^.2!)LPAFPV&(V\EN>A_"HM#U?PM=K9:/97T5W+;*
M#;F1""Q7JR,0 ?\ @/\ *HO$OA:^U74KF[M-7@LDNK#[!,LMOYA*DL<@[A@_
M-^E6[WP])-;>'K=9+=!IMQ'*T@7:6"*1M0?[1Z\]/6@"YXFBM'T*=[V\%G%"
M5F%PRA@C*05)4\-SCCO7+:1KUKIOVF\U2/5KE;A562\?2&A@$:YP<#/'S'DY
MKK/$.C+KNCR61F,#[TECE"[MCHP920>HR!Q62T?C2Y@:W^U:"B,-AN8UD9A_
MM!#\N?;.* .BL?LOV& V/E_92@,7E_=VGD8]JXTV>G:7%!J%SXDA;0X;K?!"
MMNA8RAC\OF+EFPV> ,\8/>NKT33(-&T2STZV<R0VT0C5V.2V.]<QIG@G4;'4
M=-DFU:VN++3[B:>&#[)M;,I8G+;N2-W!QVH Z+1]1T?6/.OM+EBE8D1S.JE7
MR.@8$ @\]ZPO%[QV>HVUQ;ZG);ZC/%Y*V\5B+MYD!)^5.HP2><XK4T_3U@\7
MZS??:+?=<0P+]GC;+J%W?.X[$Y('LO6F:OHNH/K4.MZ/<V\=ZD!MGBND)CEC
M+;L9'*D'N,T 4=$U;1 FGZ+/:WMM-'C[+_:5H8C(XYRI(QGV&/:MKQ!!:W.D
M21W=VMHF]"D[[<*X8;,AN#\V!@]>E8L^G:SJ%[ITGB.]TNUM+:[2:*&T+9FF
M'W!N?&.>P&36OXET:37M#DL(KE;>1I(Y%E9-X!1U<<9&?N^M &'%J&D^%]1N
M!K^O17.H3Q*KA+78J1C.-RH#CJ>6-=99I;)9Q"S$8MBN8_*QMVGD8QVKFM)T
MU]%U&_35-1L[S4M:)>-!;F(/Y<84KU;Y<8_,UK^&M)DT/PY8Z9+*)9+>+8SK
MT)SGCVYH XR26UL]::UM[O4=2L;.Z\YK6QTL2F*4-OVM,.O/;KV)KL-%U72M
M8FN+BR0I=IB.YCEB,<R=P'!Y^E9=OHOB+0FN(-$GTR>QEG>=$O0ZO$78LPW)
MG<,D]<5>T31;VVU.\U?5;F&;4+M$B*6Z%8HHTR0HSRQRQY- $>M::;S6(WL=
M9AL=1%N0Z20)-NA#==K$$8)ZU5T35O"LL=GH=MJ$-Y+"Q,1D0@.X))*-@*3G
M/W33_$/AC4-5U8WVGZI#9E[%[&59+;S=R,V20=PP:?<>&)9-$T'38Y(!_9MQ
M!(TH4KD1]=HYY;&#SW- &GXAAM9M"NA>W0M8$42-.0"(RI# D'@\@<=^E<AH
M^NV]A+/J.HKJ]ZLT80W@T=H8!$"3G R2.3R>U=AKVD1Z]HESILDK1"8#$BC)
M5E8,IQWY XK),7C@Q^1]HT(#&W[3LEW_ .]LZ9]LXH WM.:RDT^"33C$;-UW
MQ&+[I!YXKD;BRL+%6OY_$D"Z'%>&0PB!"WG"3<4\P?,3OSP!GM71^&["TTSP
M]9V5C<K=6\2D+,K ASDECQQU)^E<];>"-0@U.UE?5K>6QMM1EOX[<VF&W.6)
M!;=VWG''4"@#H-'U/1M:DFO=,EBEE7$<S!"CCN P(!^F:Y_Q8T5IK"M:ZG-%
M?7<(62T@T\7<DD:D_,!_#U/)X/IQ6S;:>L?C:_U W%N'ELXHA;HW[P@,Q\QA
M^.T=>E0:KI&HP:Z=;T>[M$N98%MYH+U3Y<BJ25(9>5(W'US0!%HVKZ+/)8:2
M]K=VMU;QC[(FHVQBD8*,94D8)QUQ6GXBM;>[T^*.:^2RD\]#;S.%8>;G"C:W
M#9)Z5F)H^M:EJVGWFOW.GQQ6,IE@M[(,=\FTJ"S/S@ G@"M#Q-HT^MZ=!#;7
M:6L]O=1722O%YB@HVX9&1_.@#%@U/1/#=Y>6VMZ[!<ZA<;/M!^S;$50"%#*H
M(7@GECS]*Z^WCABMXTMU5854! G0+VQ[5S>E>';JRTC6HY[NSOKG4I))6D$/
MEH69 N&Y;@8_4UL:%8'2] T^P:83-;6Z1&0?Q[5 S0!PMO<6MGJD<4%UJ6K:
M?ITQ,<5CI6X1N,C:TP^]C)Z=>YKM=$U+2M66XN]. $I8)<JT9CD5AV=3SGFL
M*VT[7_#%G)9Z9>Z/+ID!9T-^7C>%22V&*Y! R>3BM'PO8%6O=8FU&VO[K460
MR26F/)54!"JO)SC)Y/6@"+6--^U:Q++9:Y!8W0ME^U1R0)-^Z!;#88_+R6YZ
M'TXINAZQX7O19:387L5U+:(/L_F(03M&-R,0 W_ :K^)/"=]JVI7EQ::O!9Q
MWUB+&9)+;S"5RQRIW#!^:I[G3[?4+O0[&WO[ W&CSK-.D;CS%"H5VA!DJ"2,
MY].] &AXHCM&T.66\O191P,LRW#('",IRI*G[W/;O7,:1KUIIJW5UJT6K3K<
MA1+>2:088!&N=O SQ\QY.>M=5XCTA-:TAK5KG[-(LB3138#!)$8,I(/49'2L
M#4+SQ/';+;7NI>'K6*Y=;87*"1W+-P,(>,GW.* .NLQ;"RA^Q^7]FV Q>7]W
M;VQ[45#H^G0:1HUGIUL[/#;1+$C,<D@#&:* +M%%% !1110 4444 %%%% !7
M+^)/!=EKE\FI^1;27T<8C"W<?F12*"3@CJ.2?F'/UKJ** //O#7A6VB\8WEY
M/X9BT](((/L^ K()@7WM&P]BO. :Z#QI:7=[X>,%K'+*&N(?/BB.&DAWCS%'
MU7-7]'TD:0M\!.TWVJ\ENOF7&S><[?PK2H X[_A"-,LCK$ILXKBSFMPEK9B/
M=Y "G>$!/&YL'C'-;GAF"\M?"^EV^H%C>1VT:S;CD[@!G-.N=(%QXBL=6^T,
MIM(98?*"\/O*\Y]MOZUIT >>Z7X)^W6=M<ZA"8=274'?47F!;[9&'8A3S@K]
MPC/'R]*WM TR33_$VOO#:_9M.F,!A0+M1I IWLH_[Y&?:M/7M*&N:#>Z69V@
M%S$8_-49*Y[XJ^B[(U7.< #- '*ZOH$>M^,X?[5LC=Z4E@1$KY,:3;_F)'J5
MQ@^QK*O]"UK3]1T73K99=0T:+4HKB.5FW2VBKG*,3]Y.>#U'0UZ#6;H^D#23
MJ!$[3?;+R2ZY7&S<!\H]<8H I>,[6\O?#,]O9+*[/)&)4A.'>+>/, ]RN:SK
MKPP^@9U#PG L3!<3Z;N(BN5QV_NN.Q[]#785F7>D"ZU_3M5^T,ALHYD\H+P_
MF!>2>V-OZT 5/!-I<6'@O2;6[A>&XBMU5XW'*GT-96F^%=5FCN&U3Q!K<4PN
M) GD7:A&CW90@;3C@@8/I79UGZYI@UK0K[3#,T NH6B\U1DID8SB@#)T'PU<
MZ-XBU*]DOI[R"Y@AC22YEWRY0OD$X Q\PQ^-&LZ+JFI^)+9X]2U"UTO[,RR?
M8[A8RLH;()!!SD$CCIBNCAC\J"./.=BA<^N!3Z .-OO!5R]QILT.MZE=_9KZ
M&X>*^N0R;5.3@!?O>E=E69I.D#2IM2D%PTOVV[:ZP5QLRJC:/7[OZUIT 59]
M.M;G4+2^ECW7%H'$+[B-N\ -QT.0!UJU110 4444 %%%% &3XFMM1O/#MY#I
M,SPWY4&)D<*V0P) )X&0",^]9J>$)&12WB7Q$K$ E?MBG!]/N5U%% &+X2TB
M?0O#%EIETZ/- &#,A)!R['J0.QK(LO"^JW,]^^I:]K4!^UR&#[/=J$:(G*X&
MTD8SC!]*[&B@#F-&\,7.D>*;K46U"XO;>:S2!7NY=\H8.Q(X &W!'XYJ#4?#
MD6M^-)3K%D;O35L%%KO),<<F\[_HQ&W!]C7744 >?W.BZY8Z[H-@JRZAI%M?
MBXBNG;,MN@C==DF?O#YAANO8UO\ C.SNK_0EM[:.62-KF'[3'"<.\&\;P,<]
M*Z&B@#C-2\,3Z%!/=^%8 J/&R7&EAL1S C&Y.RN/R/>MKPE:S67A#1[6YB:*
M>&SB21&'*L% (-;-% 'GNC^"?MEE875_"8=12]>34S,"WVU0S8!YP5SL(SQQ
MTK>\/:9)I_B'Q T5J;;3II83 @7:I<)^\91Z$[?RKI** .0UCP^=:\8/]OMG
MELET[%I*<[8)]YW-P>&P5P?8U7/A9],/A9+2 27]K<@WE]&FTNFQO,+GJ=S$
M<'-=O10!FZ[H=EXBTJ33K]6:%V5OE."&!R#^?8\5P&J>"$@DT^T'AJRN%^W0
M%[VTB";H0WSB5,\<=<9!]J]1HH AM;6"QM(K6UB2&")0D<:# 4#H!14U% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >8Z5XSU+3X]9EU6Y-PC
MBYDT\,JKAHIFC\L8'/)0\^M;?A/5]5A\.ZG)J[W&IWMG?O;D0QJ'; 3@ 8&
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < $8# 2(  A$! Q$!_\0
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M;S =T@G,*Y8#@%L$G!P/6CI<.MCH:*R]#U:358+E;BV6VN[2X:WN(DD\Q X
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; - # 2(  A$! Q$!_\0
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@VIQQ7$813O160@9(R.1VQ4=5YM+\5_D4]GY7?X,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; - # 2(  A$! Q$!_\0
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MXPA6P1G"2@$X)&2.A(Z4LFM?#R76%U5_$>BF[!4Y_M90A91A6,>_86 X#$9
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BVOM3CBN(PBG>BLA R1D<CMBHZKS:7XK_ "*>S\KO\&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  / + # 2(  A$! Q$!_\0
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67@E/OMP"!\W>J6K_ *[7_#;Y S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (^ X8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BHYYXK:WDGGD6.*)2[NQP%4#))KG[/Q[X:O[]+.#4U\
MYVVIOC9%8^@8@ _G0!TE%9.N^)-+\-PP2ZI<-"D[E(]L;.6(&<84'M2:'XET
MOQ&D[:9.\H@($F^%X\$]/O 9Z4 :]%8&I^-?#VCZA]AOM12.X&-RA68)G^\0
M"%_&MV.1)8UDC8.C %64Y!'J* '4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'_@.:/[8'_0/U#_P'-:5% &;_; _Z!^H?^ YH_M@?] _4/\ P'-:5% &;_;
M_P"@?J'_ (#FC^V!_P! _4/_  '-:5% &;_; _Z!^H?^ YH_M@?] _4/_ <U
MI44 9O\ ; _Z!^H?^ YH_M@?] _4/_ <UI44 9O]L#_H'ZA_X#FC^V!_T#]0
M_P# <UI44 9O]L#_ *!^H?\ @.:/[8'_ $#]0_\  <UI44 9O]L#_H'ZA_X#
MFC^V!_T#]0_\!S6E10!F_P!L#_H'ZA_X#FC^V!_T#]0_\!S6E10!F_VP/^@?
MJ'_@.:/[8'_0/U#_ ,!S6E10!F_VP/\ H'ZA_P" YH_M@?\ 0/U#_P !S6E1
M0!F_VP/^@?J'_@.:/[8'_0/U#_P'-:5% &;_ &P/^@?J'_@.:/[8'_0/U#_P
M'-:5% &;_; _Z!^H?^ YH_M@?] _4/\ P'-:5% &;_; _P"@?J'_ (#FC^V!
M_P! _4/_  '-:5% &;_; _Z!^H?^ YH_M@?] _4/_ <UI44 9O\ ; _Z!^H?
M^ YH_M@?] _4/_ <UI44 9\.K1S74=NUM=0O("5,L14' R>:T*SKS_D,:9]9
M?_0:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,;P[_ *K4O^PC/_Z%6S6-X=_U6I?]A&?_ -"K9H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,Z\_Y#&F?67_ -!K1K.O
M/^0QIGUE_P#0:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,;P[_JM2_P"PC/\ ^A5LUC>'?]5J7_81G_\ 0JV:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#.O/\ D,:9]9?_ $&M&LZ\_P"0QIGUE_\ 0:T: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** (+VU%[8W%JTDD8FC:,O&<,N1C(/K7(6
M7PWCTZV6VLO$WB"W@4Y$<5TJJ/7@+7;44 96MZ!9Z_91V]V95:)Q)#/$^V2)
MQ_$I[&H="\,6FA33W*SW5Y>S@++=7<GF2,HZ+GL*VZ* .6U'P'IVH7]Q<I>:
MA9I=G-U!:S[(YSZL,=_;%=':VL%C:16MM&L4$*!(T7HH'05-10!C>'?]5J7_
M &$9_P#T*MFL;P[_ *K4O^PC/_Z%6S0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9UY_P AC3/K+_Z#6C6=>?\ (8TSZR_^@UHT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 8WAW_5:E_V$9_\ T*MFL;P[_JM2_P"PC/\ ^A5LT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445'-<0VZAII4C!
M. 7;&30!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G7G_(8TSZR
M_P#H-:-9UY_R&-,^LO\ Z#6C0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!C>'?\ 5:E_V$9__0JV:QO#O^JU+_L(
MS_\ H5;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<=\0U#:98*1D&\0$5V-</\ $RXCCTNRB+@2FX#JO? ZFN;%
M.U&1%3X6=NOW1]*6F1,'A1U((9001WI]=)84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &=>?\AC3/K+_P"@UHUG7G_(8TSZR_\ H-:- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-X=_U6I?\ 81G_
M /0JV:QO#O\ JM2_[",__H5;- !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !12$A02Q  ZDURG@[4[B[O-9M9YC*L5QOA+')V-GI[
M<?K6<IJ,E%]1-V:1UE<QXXUEM+\/-]GF*7-PXCB9#R.<D_EQ^-;FJRR0:1>3
M0J&D2%V4$]2 :\=M7FUR#3=(CW&5+PLD9))2,JI)R?<$US8JLX+D6[1G4E;1
M'J'@^TGL_#%I'<JRS,"[JPY!))YK=HHKKA'EBHKH:)65ADL4<T;1RH'1A@JP
MR#7E7BGP=#H.AK<I(99C<G<YXQ&0<#'L:]8JGJ.EV>K6X@O81+$&#!2>XK'$
M4%5C;KT)G!21ROPZT*?3;&>^ND,<EU@(C#!51GD_6N#\5:?=:9X@NEN0%\^1
MIHR#G<I)P:]Q50JA0, # %8OBC1X=4T6[Q:I+=K"PA;'S ]@#7/6PB=%0CT(
ME3]VRZ',Z?IT<WPLE,449F>-Y2SKDY!R3GUP*XRYU#5=6L?LEQ=B7R7+) 0-
MPVKR>.@ %>M>%M/DL?"UE:7,9$GE_O$;L3U%,@\(:'9NTMO8(LA1D')Z$8(_
M(U$\+*<8V=M+,3IMI6+?A^[6^\/6%PK%@\"Y)&,D#!_4&M*O/?#WB:+P[X5\
MK48G$L%RT"PK]_UY'H*[^&43P1RJ" ZA@#[C-=E"JIQ2ZV1I"2:'T445N6%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!G7G_(8TSZR_^@UHUG7G_(8TSZR_^@UHT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WAW_5:E_V
M$9__ $*MFL;P[_JM2_[",_\ Z%6S0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<XCC)=(I0"'V]>"!D=:;I5W_ ,)5XUAUNUM[B/3-/M7ABFFC,9EDD(W8!YP
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MTSZR_P#H-:- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ1IEII&GI:V</E1_>(SDEB.2?>KU%%>@DDK(V6@4444P"BBB@ HHHH ****
M"BBB@#@M1T^"Z^*EF)$X$ F/'#,N<5WM9']A@^*CK33%L6_DK$1]TYY.:UZP
MHP<7)OJR(JUPHHHK<L**** "BBB@ HHHH \\U-5M_BYIYB&TS1J9,?Q<,/Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .A5LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=>?
M\AC3/K+_ .@UHUG7G_(8TSZR_P#H-:- !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &-X=_P!5J7_81G_]"K9K&\._
MZK4O^PC/_P"A5LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &=>?\AC3/K+_P"@UHUG7G_(8TSZR_\ H-:- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%<OJ7CS3-.O[BU%KJ%T
MMJ<74]K;EX[<_P"T?\,UT=K=07MK%=6TBRP2J'1U/# ]#0!E^'?]5J7_ &$9
M_P#T*MFL;P[_ *K4O^PC/_Z%6S0 4444 %%%% !1110 4444 %%%% !1110
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M22!7AM^KE<]2>GXUTU9NNZ[I_AS1Y]4U*<16T*Y/JQ[*H[D] * .2\-:]?\
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M. 4DW H1G^(,!QU[5=\/>*=/\3M?-IHEDM[2;R/M)3$<S#KL/\0!XS7!^&O
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M4T;5(PEG>LV4DE[HQ_@?NIK'TN/^QO$VE^&/%\']H""1G\/ZM*I;?Q_JW])
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M(M,9#YL%R&'SJ?[HY._TH VM!)LO%EAX?\86ZW>K62NVB:NZY%S%CY@>PD
MSZXS]?2JR/#NGZA8Z'96VM7D>H:A;J5:Z$>TMZ'ZXQD]ZOI?6LE]+8I<1-=1
M(LDD(8;U5LX)'H<&@"Q7F=SJ=Y\0/&%WH>E:WJ&B6FD1DW8A3RKB28N57&<_
M)@9]\BJWB_XA:Y:W.IR:(;*VT_3)?LAENH7DDO;LC(AB0$>P)_'M4$-Q)XUQ
MKVBQC1_'VC#R[NQEX$R]XI!W1NQ[&@#3TBX(\2V/AKQQ!%=ZK9NTVCZDZ86Z
M7')]!(!U'MFO2:IV8:]L[.ZO[%(+P(',3$.87(^8!OS&15F99&@D6)Q'(5(1
MRN0IQP<=Z 'UQGBO7;6TU:+1/$>F(?#VJ1>0MZQR@F)^XX_AR,8/K6/!J>M:
MS:7?@K6=2DTCQ5 !+:7]O\J7BJ<K(H[CC#+]?I5'5?'NGW/@_5M \9V8M_$$
M<)@:Q$987;D822'U!.#[4 2VUG'X:UK3?#'BF'^TM$-RLFA:A,-YAE'W89/<
M?PD__J]4KD_A_HVLZ3X.LK+Q#>)>W,85H]R?-",#"$_Q%3D9KI&OK5+Z.Q:X
MB6[D1I$A+#>R@@$@>@R* +%>=>(M<N?$OC.'P3I.J7>CRPJ\]].D>R1XP%VB
M%CP02QR?]DTOC3QMJ=AJ=Y8Z1)9V=OI<"SZGJ-[&SK'O_P!7%&HQN=JP-/U%
MOB1:P07T9\/>/M,C%U9R;2A=2,A@#R8V'#*<XS0!IDR:1JMKX6\='^U])N+A
M9-*U2Y7K*#D138XW>AZ&O4  !@# %9.BM?:EH5I)K^FPV^H+S+"")%5U/#*?
M?J.XS6M0 5RWC#Q)_P (Z]F^H::)] N"T-]=?>^S[N%++W0\@GM6)_;&J1ZE
M?>#O%%Z]I/J/F?V5K%J/+$JGD(/[LB],=Q[]:UMXWBT&SO/#GQ%*)=00D)<F
M,F+4H<8!48^^>A7U_0 HWFG6?@_9I^HPC4_A]J4J/$22XTZ4L"O3K$3C'I_/
MUE%18U6,*$  4+T [8KS_P"$VB:OIWA )JT^^QN3YUG93)E[:,DD*2>V-IQV
MYKT*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#B?%GA>^CU%/%?A;9%KMNN)H#Q'?Q#K&_\ M>A[5AZK>R>,[#0O
M$WAS3TNY]'OFEOM'F(CE$FW:0<\;U/()Z\5ZE7!:EI4^G_%?1]0T6TN$%_%*
MNKNB8@>-1\C,>GF;L =R* %\(^%;J?6KKQAXELHH-;NG!@AC?/V2()M"$CJ3
MU/O7>444 %<SXP\(IXDMH;BUG-EK5BWF6%\@^:)_[I]4/0BNFHH Y/P;JT?B
M:U>ZU/3+>#7M,F:RN_D#&.1>NQNNT@Y_&NLK,T70-.\/PW$6G0&,7,[W$S,Q
M9GD8\DD\_P#ZJTZ .3\8>$9-9:#5]'G%CXBL?FM;H#AQWCD]4/3VKEM5O+CX
MA^$9+6UL(8/$>E7L$VH:1<G;YIC.=A/=&['I7JM<%XVTJ>+Q3X;UO1+.X.KF
M\6VGEA3]VUJ>9!,>F /NY[T 0:%X<O\ Q-XG/BSQ7I,=C) B1:;9>9N> *Q)
MD9A_$?3IBO1*** "L/Q3X7L?%>DFRN]T4L;"2VNH^)+>4='4]C_.MRB@#B?"
M&HSZM<76B^)[.VFU_0G0-<&,,)48929,CY2P'(]17;5F:?H&G:7J6HZC:P%;
MO49!)<RLQ8L0, <] /0<<UIT <[XN\)6WBFPC E:TU*U;S;*^BXD@D'0@]QZ
MCO7'W-[J'C7PKKG@S4DAT_QA%;>6P/"7*!@1)&?[C8P1VS7J5<)\4-)EGT>U
MU?2;2YD\0V-S'_9\ELF6!9@"K_\ 3,C.<\4 96F^&M5\9:M83^*O#\&EZ5I$
M'E6MBLFXO+A?G!7[JKM^6O4 ,#%-3<8UWC#8&<>M.H *SM=T+3_$FCSZ7J<
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M5/07U"3P_ISZJ@346MHS<J.@DVC=^N:T* "J]_8VNIV$]C>P)/;3H4DC<9#
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M?A6O=VT=[9SVDV[RIXVC?:Q4X88.".0>>M0:1I5EH>DVVEZ="(;2V01QH#G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
